UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)

June 15, 2015

 

SANUWAVE HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

000-52985

20-1176000

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

11475 Great Oaks Way, Suite 150, Alpharetta, Georgia

30022

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code

(678) 581-6843

 

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 1.01        Entry Into Material Defin itive Agreement .

 

( 1)      On June 15, 2015, SANUWAVE Health, Inc., a Nevada Corporation (the “Company”), and its wholly owned subsidiary SANUWAVE, Inc., a Delaware Corporation (the “Borrower”) and HealthTronics, Inc. (“HealthTronics”) entered into an amendment (the “Amendment”) to amend certain provisions of two promissory notes (the “Promissory Notes”) dated August 1, 2005 between the Borrower and HealthTronics with an aggregate outstanding principal balance of $5,372,743. The Amendment provides for the extension of the due date of the Promissory Notes to January 31, 2017. I n connection with the Amendment, the Company entered into a security agreement with HealthTronics to provide a first security interest in the assets of the Company. A copy of the Amendment is attached to this Current Report on Form 8-K (this “Current Report”) as Exhibit 10.1 , and is incorporated by reference herein.

 

(2)      In connection with the Amendment, the Company and the Borrower entered into a security agreement with HealthTronics, dated June 15, 2015 (the “Security Agreement”), to provide a first security interest in the assets of the Company to HealthTronics. A copy of the Security Agreement is attached to this Current Report as Exhibit 4.1 , and is incorporated by reference herein.

 

(3)      In addition, the Company, in connection with the Amendment, issued to HealthTronics, on June 15, 2015, an aggregate total of 3,310,000 warrants (the “Class K Warrants”) to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), at an exercise price of $0.55 per share, subject to certain anti-dilution protection. Each Class K Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after ten years. A copy of the Class K Warrant is attached to this Current Report as Exhibit 4.2 , and is incorporated by reference herein.

 

The Amendment, the Security Agreement and the Class K Warrant (collectively the “Agreements”) are included in this Current Report to provide information regarding their respective terms. They are not provided to give factual information about the Company or any other parties thereto. In addition, the representations, warranties and covenants contained in the Agreements were made only for purposes of those Agreements and as of specific dates, were solely for the benefit of the parties to those Agreements, and may be subject to limitations agreed to by the contracting parties, including being qualified by disclosures exchanged between the parties in connection with the execution of the Agreements. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Agreements instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under these Agreements and should not view the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company.

 

The foregoing descriptions of each of the Agreements contained in this Item 1.01 of this Current Report do not purport to be complete and are qualified in their entirety by reference to the Agreements.

 

Item 3.02        Unregistered Sales of Equity Securities.

 

On June 15, 2015, the Company completed the unregistered issuance of 3,310,000 Class K Warrants, pursuant to the Amendment as described in Item 1.01 of this Current Report. To the extent required by Item 3.02 of Form 8-K, the information contained or incorporated in Item 1.01 of this Form 8-K is incorporated by reference in this Item 3.02 of this Current Report.

 

 
 

 

 

The issuance of the Class K Warrants described in Item 1.01 and 3.02 of this Current Report is exempt from registration under the Securities Act, pursuant to, inter alia, Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Company has not engaged in general solicitation or advertising with regard to the issuance of these securities and is not offering securities to the public in connection with this issuance.

 

Item 7.01       Regulation FD Disclosure .

 

On June 18, 2015, the Company announced entering into the Agreements described in Item 1.01 of this Current Report. A copy of the related press release is furnished with this Current Report as Exhibit 99.1 .

 

The information in this Item 7.01 of this Current Report and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01       Financial Statements and Exhibits.

 

  (d) Exhibits.  
     
  Exhibit No. Description
     
     
  4.1 Security Agreement, dated as of June 15, 2015, entered into by SANUWAVE, Inc., and each of its domestic subsidiaries, in favor of HealthTronics, Inc.   
     
 

4.2

Class K Warrant Agreement.

 

 

4. 3

Form of Promissory Note, dated August 1, 2005, issued by SANUWAVE, Inc. to Healthtronics, Inc. (incorporated by reference to Form 8-K filed with the SEC on September 30, 2009).

 

 

10.1

Amendment to promissory notes entered into as of June 15, 2015 by and among SANUWAVE Health, Inc., SANUWAVE, Inc. and HealthTronics, Inc.

 

 

99.1

Press Release dated June 18, 2015.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SANUWAVE HEALTH, INC.

 

 

 

 

 

 

 

 

 

Dated: June 18, 2015

By:

/s/  Kevin A. Richardson II

 

 

Name: Kevin A. Richardson II

 

 

Title:   Chairman of the Board/CEO

 

 

 

 

 
 

 

 

EXHIBIT INDEX

 

 

  Exhibit No .   Description
     
  4.1    Security Agreement, dated as of June 15, 2015, entered into by SANUWAVE, Inc., and each of its domestic subsidiaries, in favor of HealthTronics, Inc.   
     
 

4.2

Class K Warrant Agreement

 

 

4. 3

Form of Promissory Note, dated August 1, 2005, issued by SANUWAVE, Inc. to Healthtronics, Inc. (incorporated by reference to Form 8-K filed with the SEC on September 30, 2009).

 

 

10.1

Amendment to promissory notes entered into as of June 15, 2015 by and among SANUWAVE Health, Inc., SANUWAVE, Inc. and HealthTronics, Inc.

 

 

99.1

Press Release dated June 18, 2015.

 

Exhibit 4.1

 

SECURITY AGREEMENT

 

THIS SECURITY AGREEMENT , dated as of June 15, 2015 (as amended, restated, supplemented or otherwise modified, this “Agreement” ), is entered into by SANUWAVE, INC. , a Delaware corporation (the “Company”), and each of its domestic subsidiaries (collectively with the Company, the Borrower ), in favor of HEALTHTRONICS, INC. , a Georgia corporation (the Lender ). Except as otherwise provided herein, capitalized terms used herein without definition shall have the meanings given to them in the Promissory Notes referred to below.

 

WITNESSETH:

 

WHEREAS , the Company and the Lender are parties to the two separate Promissory Notes, each dated as of August 1, 2005, (as amended, modified, restated or supplemented from time to time, including by that certain Amendment to Promissory Notes (the Amendment to Promissory Notes ) dated of even date herewith, the Promissory Notes ) pursuant to which Lender advanced funds and made other financial accommodations to the Company;

 

WHEREAS , as of the date hereof, the aggregate outstanding principal amount evidenced by the Promissory Notes is $5,372,743;

 

WHEREAS , the Company has requested that the Lender enter into the Amendment to Promissory Notes to, among other things, extend the maturity date thereof to January 31, 2017 and the Lender has required as one of the conditions of entering into such Amendment to Promissory Notes that the Borrower enter into this Agreement to secure the payment in full of all obligations under the Promissory Notes;

 

Whereas , the Borrower will derive substantial value and benefit from the Lender agreeing to enter into the Amendment to Promissory Notes; and

 

WHEREAS , the Lender is relying on this Agreement in its decision to continue to extend credit to the Company under the Promissory Notes, and would not enter into the Amendment to Promissory Notes without the execution and delivery of this Agreement by the Borrower.

 

NOW THEREFORE , for and in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Borrower and the Lender, intending to be legally bound, do hereby covenant and agree as follows:

 

 
 

 

 

ARTICLE 1

 

DEFINED TERMS AND PRINCIPLES OF CONSTRUCTION

 

1.1     Defined Terms.

 

(a)     Capitalized terms that are used in this Agreement and not defined in this Agreement shall have the meanings ascribed to them in the Promissory Notes. Unless otherwise defined herein or in the Promissory Notes, all terms defined in the Uniform Commercial Code as in effect in the State of Delaware (the “UCC” ) which are used herein (whether or not capitalized herein or in the UCC) shall have the respective meanings given those terms in the UCC.

 

(b)     The following terms shall have the meanings herein specified:

 

“Bankruptcy Code” shall mean Chapter 11 of Title 11 of the Federal Bankruptcy Code. (11 U.S.C. §101 et seq .).

 

“Collateral” shall have the meaning specified in Section 2.1(a).

 

“Contracts” shall mean all contracts and agreements to which the Borrower now is, or hereafter will be, bound, or a party, beneficiary or assignee all exhibits thereto and all other instruments, agreements and documents executed and delivered with respect to such contracts and all revenues, rentals, Proceeds and other sums of money due and to become due from any of the foregoing.

 

“Copyrights” shall mean any United States copyright owned by the Borrower now or hereafter, including any registration of any copyrights in the United States Copyright Office or any equivalent governmental agency or office of any foreign country, as well as any application for a copyright registration now or hereafter made with the United States Copyright Office or such other copyright office by the Borrower.

 

“Financing Statements” shall mean all financing statements, recordings, filings or other instruments of registration necessary and appropriate to perfect a security interest or Lien in any Collateral by filing in any appropriate filing or recording office in accordance with the Uniform Commercial Code as enacted in any and all relevant jurisdictions or any other relevant applicable law.

 

“Insurance Policies” shall mean all insurance policies to which the Borrower now is, or hereafter will be, a party.

 

“Marks” shall mean all right, title and interest in and to any trademarks, service marks and trade names now held or hereafter acquired by the Borrower, including any registration or application for registration of any trademarks and service marks now held or hereafter acquired by the Borrower, which are registered in the United States Patent and Trademark Office or the equivalent thereof in any State of the United States or in any foreign country, as well as any unregistered marks used by the Borrower, and any trade dress including logos, designs, company names, business names, fictitious business names and other business identifiers used by the Borrower.

 

 
-2-

 

 

“Patents” shall mean any patent to which the Borrower now or hereafter has title and any divisions, reissues, continuations, continuations-in-part or extensions thereof, as well as any application for a patent now or hereafter made by the Borrower.

 

“Proceeds” shall mean any “proceeds,” as such term is defined in the UCC or under other applicable law, and, in any event, shall include, but shall not be limited to, (i) any and all proceeds of, or amounts (in any form whatsoever, whether cash, securities, property or other assets) received under or with respect to, any insurance, indemnity, warranty or guaranty payable to the Lender or the Borrower from time to time, and claims for insurance, indemnity, warranty or guaranty effected or held for the benefit of the Borrower, with respect to any of the Collateral, (ii) any and all payments (in any form whatsoever, whether cash, securities, property or other assets) made or due and payable to the Lender or the Borrower from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any governmental authority, and (iii) any and all other amounts (in any form whatsoever, whether cash, securities, property or other assets) from time to time paid or payable, in all events, under or in connection with any of the Collateral (whether or not in connection with the sale, lease or other disposition of the Collateral).

 

“Secured Obligations” shall mean (i) the unpaid principal of and interest on (including, without limitation, interest accruing at the then-applicable default rate and interest accruing at the then-applicable rate provided in the Promissory Notes after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or similar proceeding, relating to the Borrower whether or not a claim for post-filing or post-petition interest is allowed in such proceeding), when and as due, whether at maturity, by acceleration, upon one or more dates set for prepayment or otherwise, and (ii) all other obligations and liabilities of every nature of the Borrower from time to time owing to the Lender or any assignee, in each case whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred (including monetary obligations incurred during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), which may arise under, out of, or in connection with, the Promissory Notes or any this Agreement or under any other document made, delivered or given in connection with any of the foregoing, in each case whether on account of principal, premium, if any, interest, fees, indemnities, costs, expenses or otherwise (including all fees and disbursements of counsel to such Persons) that are required to be paid by the Borrower pursuant to the terms of this Agreement or the Promissory Notes, including, without limitation, any contingent or unliquidated Secured Obligations related to unresolved claims, causes of action or liabilities which have been asserted or threatened against the Lender or which otherwise can be reasonably identified by the Lender based on then known facts and circumstances.

 

“Secured Parties” shall mean the Lender and any assignee thereof.

 

“Trade Secret Rights” shall mean the rights of the Borrower in any Trade Secret it holds.

 

“Trade Secrets” shall mean any secretly held existing engineering and other data, information, production procedures and other know-how relating to the design, manufacture, assembly, installation, use, operation, marketing, sale and servicing of any products or business of the Borrower whether written or not written.

 

 
-3-

 

 

ARTICLE 2

 

GRANT OF SECURITY INTEREST

 

2.1     Assignment and Grant of Security Interest.

 

(a)     As collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all of the Secured Obligations, whether now existing or hereafter arising and howsoever evidenced, the Borrower hereby assigns, transfers and grants to the Lender and hereby creates in favor of the Lender, for the benefit of the Secured Parties, a continuing Lien on and first priority security interest in, and right of set-off against, all of the right, title and interest of the Borrower, to and under all personal property and fixtures of the Borrower, whether now existing or hereafter from time to time acquired, including, without limitation, the following (collectively, the “Collateral” ):

 

  (1)  all Accounts;
     
  (2) all Chattel paper;
     
 

(3)

all Deposit accounts;

     
  (4)   all Documents;
     
  (5)    all Equipment;

 

 

(6)

all General intangibles (including all Payment intangibles, Contracts, Software, Copyrights, Marks, Patents, Trade Secret and Trade Secret Rights, and other intellectual property rights, including all applications, registrations and licenses therefor and all goodwill of any business connection therewith or represented thereby);

 

 

(7)

all Goods (including rights to returned or repossessed goods and rights of stoppage in transit);

     
  (8)  all Instruments (including, without limitation, Promissory notes);
     
  (9)   all Inventory;

 

 

(10)

all Investment property (including certificated and uncertificated Securities, Securities accounts, Security entitlements, Commodity accounts and Commodity contracts);

     
  (11)   all Letters of credit and Letter-of-credit rights;
     
  (12)    all Supporting obligations;

 

 
-4-

 

 

  (13)   all monies;
     
  (14)   all oil, gas or other minerals;
     
 

(15)

all governmental approvals;

     
  (16)   all Fixtures;
     
  (17)  all Insurance Policies;

 

 

(18)

all Commercial tort claims (as described on Appendix G hereto or in any writing delivered pursuant to Section 2.4(f) hereof);

 

 

(19)

all As-extracted collateral;

 

 

(20)

without limiting the generality of the foregoing, all other personal property or interests in personal property, credits, claims, demands and assets of the Borrower, whether now existing or hereafter acquired from time to time and whether or not of a type which may be subject to a security interest under the UCC;

 

 

(21)

all supporting evidence and documents relating to any of the above-described property, including, without limitation, computer programs, disks, tapes and related electronic data processing media, and all rights of the Borrower to retrieve the same from third parties, written applications, credit information, account cards, payment records, correspondence, delivery and installation certificates, invoice copies, delivery receipts, notes and other evidences of indebtedness, insurance certificates and the like; and

 

 

(22)

any and all additions and Accessions to any of the foregoing, all improvements thereto, all substitutions and replacements therefor and all products and Proceeds thereof.

 

(b)     The security interest granted to the Lender pursuant to this Agreement extends to all Collateral of the kind which is the subject of this Agreement which the Borrower may acquire at any time during the continuation of this Agreement, whether such Collateral is in transit or in the Borrower’s, the Lender’s, any Secured Party’s, or any other Person’s constructive, actual or exclusive occupancy or possession.

 

2.2     Security Interest Absolute. All rights of the Lender and all security interests created hereunder shall be absolute and unconditional irrespective of any circumstance or occurrence whatsoever, including, without limitation:

 

(a)     any lack of validity or enforceability of all or any part of the Secured Obligations or of any security therefor or of either Promissory Note or any other agreement or instrument relating thereto;

 

 
-5-

 

 

(b)     any change in the time, manner or place of payment of, or in any other term of, all or any part of the Secured Obligations, or any other amendment or waiver of or any consent to any departure from or exercise or non-exercise of any right under either Promissory Note or any other agreement or instrument relating thereto; or

 

(c)     any exchange, release or non-perfection of any other collateral for, or any release or amendment or waiver of or consent to any departure from any guaranty for, all or any part of the Secured Obligations.

 

2.3     Power of Attorney.

 

(a)     Without limiting any other rights or powers granted to the Lender hereunder, the Borrower hereby constitutes and appoints the Lender, or any Person or agent whom the Lender may designate, as the Borrower’s attorney-in-fact for the purpose of carrying out the terms of this Agreement during the existence of an Event of Default, at the Borrower’s cost and expense, to exercise all or any of such powers in accordance with Article 9 of the UCC, which powers, being coupled with an interest, shall be irrevocable until the indefeasible payment in full in cash of all of the Secured Obligations, including, without limitation, the following:

 

(i)     to receive, take, endorse, sign, assign and deliver, all in the Lender’s name or in the Borrower’s name, any and all checks, notes, drafts and other documents or instruments relating to the Collateral;

 

(ii)     to receive, open and dispose of all mail addressed to the Borrower and to notify postal authorities to change the address for delivery thereof to such address as the Lender designates;

 

(iii)     to request from account debtors of the Borrower in the Borrower’s name or in the Lender’s name, information concerning the Accounts and the amounts owing thereon;

 

(iv)     to transmit to account debtors indebted on Accounts notice of the Lender’s interest therein;

 

(v)     to notify account debtors indebted on Accounts to make payment directly to the Lender;

 

(vi)     to take or bring, in the Borrower’s name or in the Lender’s name, all steps, actions, suits or proceedings deemed by the Lender to be necessary or desirable to enforce or effect collection of the Accounts;

 

(vii)     to prepare and file any Financing Statement in the name of the Borrower as debtor for the purpose of perfecting Liens;

 

(viii)     to take or cause to be taken all actions necessary to perform or comply or cause performance or compliance with the covenants of the Borrower contained in any other agreement entered into in connection herewith in accordance with this Agreement;

 

 
-6-

 

 

(ix)     to sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications, notices and other documents in connection with any of the Collateral;

 

(x)     to defend any suit, action or proceeding brought against the Borrower;

 

(xi)     to settle, compromise or adjust any suit, action or proceeding described in the preceding clause and, in connection therewith, to give such discharges or releases as the Lender may deem appropriate;

 

(xii)     generally, to sell or transfer and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though the Lender were the absolute owner thereof for all purposes, and to do, at the Lender’s option and the Borrower’s expense, at any time, or from time to time, all acts and things which the Lender deems necessary to protect, preserve or realize upon the Collateral and the Liens of the Lender thereon, consistent with any express requirement of the UCC;

 

(xiii)     to execute, in connection with any foreclosure, any endorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral;

 

(xiv)     to perform (including, without limitation, by satisfying any payment obligation), or cause the performance of, any Contract;

 

(xv)     to defend the title to the Collateral against the claims and demands of any Person;

 

(xvi)     to exercise any and all of the Borrower’s rights, powers and remedies under any Contract in accordance with Section 7.4; and

 

(xvii)     to exercise any and all other rights, remedies, powers and privileges of the Borrower with respect to the Collateral.

 

(b)     The Borrower hereby ratifies all that said attorney shall lawfully do or cause to be done by virtue hereof, in each case pursuant to the powers granted hereunder. The Borrower hereby acknowledges and agrees that in acting pursuant to this power-of-attorney the Lender shall be acting in its own interest and on behalf of the Secured Parties, and the Borrower acknowledges and agrees that the Lender and the Secured Parties shall have no fiduciary duties to the Borrower and the Borrower hereby waives any claims to the rights of a beneficiary of a fiduciary relationship hereunder.

 

2.4     Borrower’s Duties. (a) Anything herein contained to the contrary notwithstanding, the Borrower shall remain liable to perform all of its obligations under or with respect to the Collateral, including any Contract or governmental approval, and neither the Lender nor any other Secured Party shall have any obligations or liabilities under or with respect to any Collateral by reason of or arising out of this Agreement, nor shall the Lender or any other Secured Party be required or obligated in any manner to perform or fulfill any of the obligations of the Borrower under or with respect to any Collateral.

 

 
-7-

 

 

(b)     If any Collateral is in the possession of a third party, the Borrower will promptly notify the Lender of this fact and shall provide in such notice to the Lender (i) the name, address and telephone number of such third party, and (ii) a description of the Collateral in such third party’s possession. The Borrower agrees, at any time upon the Lender’s request, to notify such third party of the Lender’s security interest in such Collateral, to obtain an acknowledgment from such third party that it is holding such Collateral for the benefit of the Lender and to obtain such other agreements and lien waivers from such third party as the Lender may require.

 

(c)     The Borrower shall cooperate with the Lender in obtaining control with respect to collateral consisting of Deposit accounts, Investment property, Letter-of-credit rights and Electronic chattel paper.

 

(d)     The Borrower shall place a legend on any chattel paper or electronic chattel paper created by the Borrower. Such legend must either be in a form and substance acceptable to the Lender or be in the following form:

 

THIS CHATTEL PAPER IS SUBJECT TO THE TERMS OF THE SECURITY AGREEMENT AMONG SANUWAVE, INC. AND HEALTHTRONICS, INC., AS LENDER, INCLUDING, WITHOUT LIMITATION, LIMITATIONS ON THE RIGHTS TO TRANSFER THIS CHATTEL PAPER, AND REFERENCE IS HEREBY MADE TO SUCH SECURITY AGREEMENT FOR A FULL STATEMENT OF SUCH TERMS. A COPY OF THE SECURITY AGREEMENT IS AVAILABLE FOR INSPECTION AT THE PRINCIPAL OFFICE OF SANUWAVE, INC. AND WILL BE FURNISHED BY SANUWAVE, INC. TO THE REQUESTOR AT NO COST UPON WRITTEN REQUEST.

 

(e)     If the Borrower at any time is a beneficiary under a letter of credit now or hereafter issued, the Borrower shall promptly notify the Lender thereof and the Borrower shall, at any time upon the Lender’s request, pursuant to an agreement in form and substance satisfactory to the Lender, either (i) arrange for the issuer and any confirmer of such letter of credit to consent to an assignment to the Lender of the proceeds of any drawing under the letter of credit, or (ii) arrange for the Lender to become the transferee beneficiary of the letter of credit.

 

(f)     If the Borrower shall at any time hold or acquire a Commercial tort claim, the Borrower shall immediately notify the Lender in writing signed by the Borrower of the details thereof and shall grant to the Lender in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance satisfactory to the Lender.

 

(g)     If the Borrower at any time holds or acquires an interest in any electronic chattel paper or any “transferable record,” as that term is defined in Section 201 of the federal Electronic Signatures in Global and National Commerce Act, or in §16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, the Borrower shall promptly notify the Lender in writing thereof and shall take such action as is necessary to vest in the Lender control under Section 9-105 of the UCC of such electronic chattel paper or control under Section 201 of the federal Electronic Signatures in Global and National Commerce Act or, as the case may be, §16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record.

 

 
-8-

 

 

2.5     Effective as a Financing Statement. This Agreement shall also be effective as a Financing Statement covering any Collateral and may be filed in any appropriate filing or recording office. A carbon, photographic, facsimile or other reproduction of this Agreement or of any Financing Statement relating to this Agreement shall be sufficient as a Financing Statement for any of the purposes referred to in the preceding sentence.

 

ARTICLE 3

 

GENERAL REPRESENTATIONS, WARRANTIES AND COVENANTS

 

The Borrower represents, warrants and covenants, which representations, warranties and covenants shall survive execution and delivery of this Agreement, as follows:

 

3.1     Necessary Filings.      All filings, registrations and recordings necessary or appropriate to create, preserve, protect and perfect the security interest granted by the Borrower to the Lender on behalf of the Secured Parties hereby in respect of the Collateral have been accomplished and the security interest granted to the Lender pursuant to this Agreement in and to the Collateral constitutes a valid and enforceable perfected security interest therein superior and prior to the rights of all Persons therein, in each case, subject to no other Liens, sales, assignments, conveyances, settings over or transfers. The Borrower authorizes the Lender to take any action not taken by the Borrower to accomplish the foregoing including, but not limited to, filing Financing Statements as set forth in Section 6.3.

 

3.2     No Liens. The Borrower has rights in, is the owner of, or has the power to transfer, all of its Collateral and such rights in, such ownership of, or such power to transfer its Collateral is free from any Lien or other right, title or interest of any Person and the Borrower shall defend such Collateral against all claims and demands of all Persons at any time claiming the same or any interest therein adverse to the Lender. Without limiting the generality of the foregoing, the Borrower shall not assign, charge, convey, sell, set over, transfer, lease, license or grant any security interest in its Collateral other than pursuant to this Agreement.

 

3.3     Other Financing Statements. There is no Financing Statement (or similar statement or instrument of registration under the law of any jurisdiction) covering or purporting to cover any interest of any kind in the Collateral (other than Liens securing the Secured Obligations) and until the indefeasible payment in full in cash of all of the Secured Obligations the Borrower will not file or permit or authorize to be filed in any public office any Financing Statement (or similar statement or instrument of registration under the law of any jurisdiction) or statements relating to its Collateral, except Financing Statements (or continuations thereof) filed or to be filed in respect of and covering the security interests granted hereby by the Borrower.

 

 
-9-

 

 

3.4     Chief Executive Office; Records. The chief executive office of the Borrower is located at the address indicated on Appendix A hereto. The Borrower shall not move the location of its chief executive office unless it has complied with the requirements of the last sentence of this Section 3.4. The originals of all documents evidencing all Collateral of the Borrower, and the original books of accounts and records concerning the Collateral are, and will continue to be, kept at, and controlled and directed (including, without limitation, for general accounting purposes) from, the Borrower’s chief executive office, or at such new location for its chief executive office as the Borrower may establish in accordance with the last sentence of this Section 3.4. The Borrower shall not establish a new location for its chief executive office until (i) it has given to the Lender not less than thirty (30) days’ prior written notice of its intention so to do, clearly describing such new location and providing such other information in connection therewith as the Lender may reasonably request, and (ii) with respect to such new location, it shall have taken all action, reasonably satisfactory to the Lender, to maintain the security interest of the Lender in the Collateral intended to be granted hereby at all times fully perfected and in full force and effect.

 

3.5     Maintenance of Records. The Borrower shall keep and maintain, at the Borrower’s own cost and expense, records of its Collateral, including, but not limited to, records of all payments received and all credits granted thereon (subject to customary record retention policies for companies of similar size located in the United States), and the Borrower shall make the same reasonably available to the Lender and the Secured Parties for inspection at the Borrower’s chief executive office, at the Borrower’s expense. The Borrower shall, at the Borrower’s cost and expense, deliver all tangible evidence that the Lender may reasonably request of the Collateral and books and records to the Lender or to its representatives (copies of which evidence and books and records may be retained by the Borrower) at any reasonable time upon the Lender’s demand. If an Event of Default occurs and continues, upon the request of the Lender the Borrower shall legend in form and substance reasonably satisfactory to the Lender, the Collateral, as well as books, records and documents of the Borrower evidencing or pertaining to the Collateral, with an appropriate reference to the fact that the Collateral has been assigned to the Lender and that the Lender has a security interest therein.

 

3.6     Maintenance of Insurance. Until the indefeasible payment in full in cash of all of the Secured Obligations, the Borrower will maintain, and will cause each of its subsidiaries to, maintain, with financially sound and reputable insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms and in such amounts as is customary in the case of entities of established reputations engaged in the same or a similar business and similarly situated. The Lender shall be named as loss payee on all property insurance policies, and as additional insured on all liability insurance policies, obtained or maintained by or on behalf of the Borrower or any of its subsidiaries. Each policy of insurance or endorsement shall contain a clause requiring the insurer to give not less than 30 days prior written notice to the Lender in the event of cancellation of the policy for any reason whatsoever and a clause specifying that the interests of the Lender shall not be impaired or invalidated by any act or neglect the Borrower or any of its subsidiaries. If the Borrower fails to provide and pay for such insurance, the Lender may, at its option, but shall not be required to, procure the same and charge the Borrower therefor.

 

 
-10-

 

 

3.7     Real Property; Location of Inventory and Equipment. Appendix B hereto sets forth all real property owned or leased by the Borrower and each of its subsidiaries. All Inventory and Equipment, except such Inventory or Equipment that is being sold to a purchaser but title to which has not yet passed to such purchaser, held on the date hereof by the Borrower is located at one of its locations shown on Appendix B hereto, such locations being listed for the Borrower on Appendix B. The Borrower shall use its best efforts to deliver to the Lender a duly executed landlord waiver with respect to the location of its chief executive office and, upon the request of the Lender, each of its other leased locations listed on Appendix B, which landlord waiver shall be reasonably satisfactory in form and substance to the Lender. The Borrower agrees that all Inventory and Equipment now held or subsequently acquired by it shall be kept at (or shall be in transport to or from) any one of its locations shown on Appendix B hereto or such new location as the Borrower may establish in accordance with the last sentence of this Section 3.7. The Borrower may establish a new location for the Inventory and Equipment if (i) it shall have given to the Lender not less than thirty (30) days’ prior written notice of its intention to do so, clearly describing such new location and providing such other information in connection therewith as the Lender may reasonably request, (ii) it shall use its best efforts to provide to the Lender a duly executed landlord waiver with respect to each new location of its chief executive office and, upon the request of the Lender, each of its other leased locations listed on Appendix B, which landlord waiver(s) shall be reasonably satisfactory in form and substance to the Lender and (iii) with respect to the new location, the Borrower shall have taken all actions necessary to maintain the security interest of the Lender in the Collateral intended to be granted hereby at all times fully perfected and in full force and effect.

 

3.8     State of Organization; Name of Borrower and Subsidiaries. The exact legal name, state of organization and organizational number, if any, of the Borrower and each of its subsidiaries are set forth on Appendix C. The Borrower shall not change its exact legal name or its state of organization until (i) it has given to the Lender not less than thirty (30) days’ prior written notice of its intention so to do, clearly describing such new state of organization and such new legal name and providing such other information in connection therewith as the Lender may reasonably request, and (ii) it has taken all action necessary to maintain the security interest of the Lender in the Collateral intended to be granted hereby at all times fully perfected and in full force and effect.

 

3.9     Business Purpose. The Secured Obligations and other transactions hereunder are extensions of credit for a business purpose and are not consumer transactions or consumer goods transactions.

 

3.10     Commercial Tort Claims. Appendix G hereto contains a true, complete and current listing of all Commercial tort claims held by the Borrower as of the date hereof, each described by referring to a specific incident giving rise to such claim.

 

3.11     Organization, Execution and Delivery of Agreement. The Borrower is a limited liability company or corporation duly organized or formed (as the case may be) and either existing or in good standing (as the case may be) under the laws of the state specified with respect to the Borrower on Appendix C herein. The Borrower has all requisite limited liability company or corporate (as the case may be) power to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by all requisite corporate action by the Borrower, and this Agreement has been duly executed and delivered by authorized officers of the Borrower and is a valid obligation of the Borrower, legally binding upon and enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization or other similar laws affecting the enforcement of creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

 

 
-11-

 

 

3.12     Conflicting Agreements and Other Matters. Neither the execution nor delivery of this Agreement, the Notes or the other documents executed in connection therewith nor fulfillment of nor compliance with the terms and provisions hereof or thereof, will conflict with, or result in a breach of the terms, conditions or provisions of, or constitute a default under, or result in any violation of, or result in the creation of any Lien (other than Liens created pursuant to the Collateral Documents) upon any of the properties or assets of the Borrower, pursuant to, the organizational document of the Borrower, any award of any arbitrator or any agreement (including any agreement with any member or stockholder, as applicable, of the Borrower), instrument, order, judgment, decree or applicable law to which the Borrower is subject. The Borrower is not a party to, or otherwise subject to any provision contained in, any instrument evidencing Indebtedness of the Borrower, any agreement relating thereto or any other contract or agreement (including its operating agreement) that limits the amount of, or otherwise imposes restrictions on the incurring of, the obligations incurred hereunder.

 

3.13       Deposit and Securities Accounts. The Borrower does not maintain any deposit account or Securities account except as set forth on Appendix D hereto. For each deposit account that the Borrower at any time opens or maintains, the Borrower shall enter into, and cause the respective depositary institutions to enter into, an agreement in form and substance reasonably satisfactory to Lender, and pursuant to such account control agreement, cause the depositary institution to comply at any time with instructions from Lender to such depositary institution directing the disposition of funds from time to time credited to such deposit account, without further consent of the Borrower. For each securities account that the Borrower at any time opens or maintains, the Borrower shall enter into, and cause the respective securities intermediary to enter into, an agreement in form and substance reasonably satisfactory to Lender, and pursuant to such securities account control agreement, cause the securities intermediary to comply with entitlement orders originated by Lender without further consent by the Borrower.

 

ARTICLE 4

 

SPECIAL PROVISIONS CONCERNING

TRADEMARKS, TRADE SECRET RIGHTS, PATENTS AND COPYRIGHTS

 

4.1     Additional Representations and Warranties. The Borrower represents and warrants that it does not own, use in its business or license any Copyrights, Marks, Patents or Trade Secrets, except as set forth on Appendix E hereto.

 

4.2     Future Registered Marks. If the Borrower acquires any other Mark after the date of this Agreement or if any registration issues hereafter to the Borrower as a result of any application now or hereafter pending before the United States Patent and Trademark Office or equivalent governmental agency in any foreign jurisdiction, within thirty (30) days after such acquisition or of receipt of the certificate evidencing such registration the Borrower shall deliver to the Lender a copy of such certificate, and, upon the request of the Lender, shall execute and deliver a trademark security agreement in form and substance satisfactory to the Lender pursuant to which all of the Borrower’s rights, title and interest in and to such Mark or Marks relating to such certificate are assigned to the Lender for the benefit of the Secured Parties.

 

 
-12-

 

 

4.3     Remedies with respect to Marks. If an Event of Default shall occur and be continuing, the Lender may, by written notice to the Borrower, take any or all of the following actions: (i) declare the entire right, title and interest of the Borrower in and to each of any Marks, together with all trademark rights and rights of protection to the same, vested, in which event such rights, title and interest shall immediately vest, in the Lender for the benefit of the Secured Parties; (ii) take, use, or sell any Marks and the goodwill of the Borrower’s business symbolized by any Marks and the right to carry on the business and use the assets of the Borrower in connection with which such Marks have been used; and (iii) direct the Borrower to refrain, in which event the Borrower shall refrain, from using any Marks in any matter whatsoever, directly or indirectly; and the Borrower shall change its corporate or limited liability company name, as applicable, to eliminate therefrom any use of any Mark and execute such other and further documents necessary to further confirm this and to transfer to the Lender for the benefit of the Secured Parties ownership of such Marks and registrations and any pending trademark application in the United States Patent and Trademark Office or any equivalent governmental agency or office in any foreign jurisdiction.

 

4.4     Other Patents and Copyrights. If after the date of this Agreement the Borrower acquires any other Patent or Copyright, a Patent or Copyright registration is issued to the Borrower, or the Borrower files an application for a Patent or Copyright registration, the Borrower shall deliver to the Lender a copy of such Patent or Copyright, Patent or Copyright registration or application for a Patent or Copyright registration, as the case may be, and, upon the request of the Lender, a patent security agreement or copyright security agreement, as the case may be, in form and substance satisfactory to the Lender, executed by the Borrower, pursuant to which all of the Borrower’s right, title and interest to such Patent, Copyright registration or application are assigned to the Lender for the benefit of the Secured Parties.

 

4.5     Remedies with respect to Patents and Copyrights. If an Event of Default shall occur and be continuing, the Lender may by written notice to the Borrower take any or all of the following actions: (i) declare the entire right, title and interest of the Borrower in each of the Patents and Copyrights vested, in which event such right, title and interest shall immediately vest, in the Lender for the benefit of the Secured Parties; (ii) take and practice, use or sell the Patents and Copyrights; (iii) direct the Borrower’s to refrain, in which event the Borrower shall refrain, from practicing the Patents and using the Copyrights directly or indirectly; and the Borrower shall execute such other and further documents as the Lender may request further to confirm this and to transfer ownership of the Patents and Copyrights to the Lender for the benefit of the Secured Parties.

 

 
-13-

 

 

ARTICLE 5

 

SPECIAL PROVISIONS CONCERNING EQUIPMENT AND INSTRUMENTS

 

5.1     Instruments. Any Instruments (including any Promissory notes) owned by the Borrower on the date hereof are listed as Appendix F hereto. If the Borrower owns or acquires any other Instrument (including, without limitation, any Promissory note), the Borrower shall, within ten (10) days, notify the Lender and deliver such Instrument to the Lender appropriately endorsed to the order of the Lender as further security hereunder.

 

5.2     Equipment. With respect to any Equipment covered by a certificate of title, the Borrower shall, upon the request of the Lender, list the Lender as the lienholder of such certificate of title on behalf of the Secured Parties and within thirty (30) days of such request deliver evidence of the same to the Lender.

 

ARTICLE 6

 

PROVISIONS CONCERNING ALL COLLATERAL

 

6.1     Protection of the Lender’s Interests. The Borrower will do nothing to impair the rights of the Lender or the other Secured Parties in the Collateral. The Borrower assumes all liability and responsibility in connection with the Collateral and the liability of the Borrower with respect to the Secured Obligations shall in no way be affected or diminished by reason of the fact that any Collateral may be lost, destroyed, stolen, damaged or for any reason whatsoever unavailable to the Borrower.

 

6.2     Further Actions. The Borrower will, at its own expense, make, execute, endorse, acknowledge, file and/or deliver to the Lender and the other Secured Parties from time to time such lists, descriptions and designations of Collateral, warehouse receipts, receipts in the nature of warehouse receipts, bills of lading, documents of title, vouchers, invoices, schedules, confirmatory assignments, conveyances, Financing Statements, transfer endorsements, powers of attorney, certificates, reports and other assurances or instruments, and take such further steps relating to the Collateral and other property or rights covered by the interests hereby granted which are required or reasonably requested to perfect, preserve or protect its ownership and security interests in the Collateral.

 

6.3     Financing Statements. The Borrower irrevocably authorizes the Lender at any time, and from time to time, to file in any jurisdiction any initial Financing Statements, amendments thereto and continuation statements that (a) indicate the Collateral (i) as all assets of the Borrower or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls within the scope of Article 9 of the Uniform Commercial Code of the jurisdiction wherein such Financing Statement or amendment is filed, or (ii) as being of an equal or lesser scope or with greater detail, and (b) contain any other information required by Article 9 of the Uniform Commercial Code of the jurisdiction wherein such Financing Statement or amendment is filed regarding the sufficiency or filing office acceptance of any Financing Statement or amendment, including, if required, (i) whether the Borrower is an organization, the type of organization and any organization identification number issued to the Borrower, and (ii) in the case of a Financing Statement filed as a fixture filing or indicating Collateral as as-extracted collateral or timber to be cut, a sufficient description of real property to which the Collateral relates. The Borrower agrees to furnish any such information to the Lender promptly upon request. The Borrower further ratifies and affirms its authorization for any Financing Statements and/or amendments thereto, executed and filed by the Lender in any jurisdiction prior to the date of this Agreement. The Borrower also agrees to sign and deliver to the Lender and the other Secured Parties such similar statements or instruments of registration under the law of any jurisdiction, in form acceptable to the Lender, as the Lender may from time to time reasonably request or as are necessary or desirable in the reasonable opinion of the Lender, as communicated to the Borrower, to establish and maintain the security interests contemplated hereunder as valid, enforceable, first priority security interests as provided herein and the other rights and security contemplated herein. The Borrower will pay any applicable filing fees and related expenses.

 

 
-14-

 

 

6.4.     Care of Collateral. The Borrower agrees it will not waste or destroy the Collateral or any part thereof and will not be negligent in the care or use of any Collateral. The Borrower agrees it will not use, manufacture, sell or distribute any Collateral in violation in any material respect of any applicable statute, ordinance or other governmental requirement. The Borrower will perform in all material respects its obligations under any Contract or other agreement constituting part of the Collateral, it being understood and agreed that the Secured Parties have no responsibility to perform such obligations.

 

6.5.     Performance By Lender. Upon the failure of the Borrower to perform any of the covenants and agreements herein contained, the Lender may, at its option, but shall have no obligation to, perform the same and in so doing may expend such sums as the Lender deems advisable in the performance thereof, including, without limitation, the payment of any insurance premiums, the payment of any taxes (other than to the extent the amount, applicability or validity thereof is being actively contested by the Borrower on a timely basis in good faith and in appropriate proceedings, and the Borrower has established adequate reserves therefor in accordance with generally accepted accounting principles on the books of the Borrower) or expenditures which the Lender may be compelled to make by operation of law or which the Lender may make by agreement or otherwise for the protection of the security hereof. All such sums and amounts so expended shall be repayable by the Borrower upon demand, shall constitute additional Secured Obligations secured hereunder, and shall bear interest from the date said amounts are expended at the default rate applicable to the Principal Amount under the Notes at such time. No such performance of any covenant or agreement by the Lender on behalf of a Borrower, and no such advancement or expenditure therefor, shall relieve the Borrower of any default under the terms of this Agreement or in any way obligate any Secured Party to take any further or future action with respect thereto. The Lender, in making any payment hereby authorized, may do so according to any bill, statement or estimate procured from the appropriate public office or holder of the claim to be discharged without inquiry (absent manifest error) into the accuracy of such bill, statement or estimate or into the validity of any tax assessment, sale, forfeiture, tax lien or title or claim. The Lender, in performing any act hereunder, shall be the sole judge of whether the relevant Borrower is required to perform the same under the terms of this Agreement. The Lender is hereby authorized to charge any account of the Borrower maintained with any Secured Party for the amount of such sums and amounts so expended.

 

 
-15-

 

 

6.6.     Assignment of Claims Act. If any Account arises out of a contract with the United States of America, or any state or political subdivision thereof, or any department, agency or instrumentality of any of the foregoing, the Borrower agrees to promptly so notify the Lender and, at the request of the Lender, execute whatever instruments and documents are required by the Lender in order that such Account shall be assigned to the Lender and that proper notice of such assignment shall be given under the federal Assignment of Claims Act (or any successor statute) or any similar state or local statute, as the case may be.

 

ARTICLE 7

 

REMEDIES UPON OCCURRENCE OF AN EVENT OF DEFAULT

 

7.1     Events of Default; Obtaining the Collateral Upon an Event of Default. If an Event of Default has occurred and is continuing, the Lender, in addition to its other rights and remedies hereunder, and the rights of the Secured Parties under each other document entered into in connection herewith, shall be entitled to do any of the following:

 

(a)     exercise any rights or remedies granted to a secured party under the Uniform Commercial Code as in effect in any relevant jurisdiction or under any other relevant law to enforce this Agreement and the security interests contained herein;

 

(b)     proceed to protect and enforce the rights vested in it by this Agreement, including, but not limited to, the right to substitute itself or any of its nominees or trustees in lieu of the Borrower, to cause all revenues hereby pledged as security and all other moneys pledged hereunder to be paid directly to it, and to enforce its rights hereunder to such payments and all other rights hereunder by such appropriate judicial proceedings as it shall deem most effective to protect and enforce any of such rights, either at law or in equity or otherwise, whether for specific enforcement of any covenant or agreement contained in any of the Contracts, or in aid of the exercise of any power therein or herein granted, or for any foreclosure hereunder and sale under a judgment or decree in any judicial proceeding, or to enforce any other legal or equitable right vested in it by this Agreement or by law whether in the Borrower’s name, in the Lender’s name or in the name of the Lender’s designees;

 

(c)     cause any action at law or suit in equity or other proceeding to be instituted and prosecuted to collect or enforce any of the Secured Obligations or any rights hereunder or included in the Collateral, or enforce or to foreclose any other agreement or other instrument by or under or pursuant to which such Secured Obligations are issued or secured, subject in each case to the provisions and requirements thereof;

 

(d)     sell, assign or otherwise liquidate any or all of the Collateral or cause the Collateral to be sold or otherwise disposed of and take possession of the proceeds of any such sale or liquidation;

 

(e)     incur expenses, including reasonable attorneys’ fees and expenses, consultants’ fees and other costs appropriate to the exercise of any right or power under this Agreement;

 

 
-16-

 

 

(f)     perform any obligation of the Borrower hereunder or under any other document entered into in connection herewith, and make payments, purchase, contest or compromise any encumbrance, charge or Lien, and pay taxes and expenses, without, however, any obligation so to do;

 

(g)     take possession of the Collateral and render it usable, and repair and renovate the same, without, however, any obligation so to do, and enter upon any location where the same may be located, control, manage, operate, rent or lease the Collateral, collect all rents and income from the Collateral and apply the same to reimburse the Secured Parties for any cost or expenses incurred hereunder or under any other document executed in connection herewith and to the payment or performance of the Borrower’s obligations hereunder or under any document entered into in connection herewith and apply the balance to the Secured Obligations;

 

(h)     secure the appointment of a receiver of the Collateral or any part thereof; and/or

 

(i)     take possession of the Collateral or any part thereof by directing the Borrower in writing to turn over the Collateral to the Lender at any reasonable place or places designated by the Lender, in which event the Borrower shall at its own expense;

 

 

(i)

forthwith cause the same to be moved to the place or places so designated by the Lender and there delivered to the Lender;

 

 

(ii)

store and keep any Collateral so delivered to the Lender at such place or places pending further action by the Lender; and

 

 

(iii)

while Collateral shall be so stored and kept, provide such guards and maintenance services as shall be reasonably necessary to protect the same and to preserve and maintain them in good condition.

 

The parties hereto hereby agree that the Borrower’s obligation to deliver the Collateral as set forth above is of the essence of this Agreement and that, accordingly, upon application to a court of equity having jurisdiction, the Lender shall be entitled to a decree requiring specific performance by the Borrower of such obligation.

 

7.2     Remedies; Disposition of the Collateral.

 

(a)     If an Event of Default has occurred and is continuing, any Collateral, whether or not repossessed by the Lender pursuant to Section 7.1, may be sold, leased or otherwise disposed of under one or more contracts or as an entirety, and without the necessity of gathering at the place of sale the property to be sold, and in general in such manner, at such time or times, at such place or places and on such terms as the Lender may, in compliance with any mandatory requirements of any applicable law, determine to be commercially reasonable, as fully and completely as though the Lender were the absolute owner thereof.

 

 
-17-

 

 

(b)     Subject to subsection (a) of this Section 7.2, any Collateral may, upon the occurrence and during the continuance of an Event of Default, be sold, leased or otherwise disposed of, in the condition in which the same existed when taken by the Lender or after any overhaul or repair which the Lender, upon consultation with such Persons, including independent consultants and engineers, as it shall deem appropriate, shall determine to be commercially reasonable. Any such disposition shall be made upon not less than ten days’ written notice to the Borrower specifying the time such disposition is to be made and, if such disposition shall be a public sale, specifying the place of such sale. Any such sale may be adjourned by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. The Borrower hereby waives any claims against the Lender arising by reason of the fact that the price at which Collateral may have been sold at a private sale was less than the price that might have been obtained at a public sale or was less than the aggregate amount of the Secured Obligations, even if the Lender accepts the first offer received or does not offer the Collateral to more than one offeree. All fees of the Lender and all expenses (including court costs and attorneys’ fees, expenses and disbursements) of, or incident to, the enforcement of any of the provisions hereof shall be recoverable from the proceeds of the sale or other disposition of the Collateral.

 

(c)     The Lender may dispose of the Collateral under subsection (b) of this Section 7.2 without giving any warranties as to the Collateral. The Lender may disclaim warranties relating to title, possession, quiet enjoyment, and the like. Such a disclaimer will not affect the commercial reasonableness of such disposition.

 

(d)     The Lender will comply with any applicable state or federal law requirements in connection with the disposition of the Collateral under subsection (b) of this Section 7.2. Such compliance will not affect the commercial reasonableness of such disposition.

 

7.3     Purchase of the Collateral. The Lender may be a purchaser of the Collateral or any part thereof or any right or interest therein at any sale thereof, whether pursuant to foreclosure, power of sale or otherwise hereunder and the Lender may apply the purchase price to the payment of the Secured Obligations.

 

7.4       Special Provisions Concerning Contracts. (a) If any default by the Borrower under any Contract that has given rise to an Event of Default shall occur and be continuing, the Lender shall in accordance with Section 7.1 be permitted (but shall not be obligated) to remedy any such default by giving written notice of such intent to the Borrower and to the parties to the Contract or Contracts for which the Lender intends to remedy the default. Any cure by the Lender of the Borrower’s default under any of the Contracts shall not be construed as an assumption by the Lender or any Secured Party of any obligations, covenants or agreements of the Borrower under such Contract, and neither the Lender nor any Secured Party shall be liable to the Borrower or any other Person as a result of any actions undertaken by the Lender in curing or attempting to cure any such default, except to the extent determined by a court of competent jurisdiction in a final, non-appealable judgment to have resulted from the gross negligence or willful misconduct of the Lender. This Agreement shall not be deemed to release or to affect in any way the obligations of the Borrower under the Contracts.

 

(b)     Upon the occurrence of any Event of Default and continuance thereof, the Lender shall have the rights set forth in Article 9 of the UCC and shall be entitled to (i) enforce all remedies, rights, powers and privileges of the Borrower under any or all of the Contracts, and/or (ii) to the extent permitted by the terms of such Contracts, substitute itself or any nominee or trustee of the Lender in lieu of the Borrower as party to any of the Contracts and notify the obligor under any Contract (the Borrower hereby agreeing to deliver any such notice at the request of the Lender) that all payments and performance under the relevant Contract shall be made or rendered to the Lender or such other Person as the Lender may designate.

 

 
-18-

 

 

7.5     Waiver.

 

(a)     EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE BORROWER HEREBY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, NOTICE OR JUDICIAL HEARING IN CONNECTION WITH THE LENDER’S TAKING POSSESSION OR THE LENDER’S DISPOSITION OF ANY OF THE COLLATERAL PURSUANT TO THE TERMS OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY AND ALL PRIOR NOTICE AND HEARING FOR ANY PREJUDGMENT REMEDY OR REMEDIES AND ANY SUCH RIGHT WHICH THE BORROWER WOULD OTHERWISE HAVE UNDER THE CONSTITUTION OR ANY STATUTE OF THE UNITED STATES OR OF ANY STATE OR UNDER ANY OTHER RELEVANT LAW AND THE BORROWER HEREBY FURTHER WAIVES:

 

(i)     all damages occasioned by such taking of possession except any damages which are finally judicially determined to have been the direct result of the Lender’s or any Secured Party’s gross negligence or willful misconduct;

 

(ii)     all other requirements as to the time, place and terms of sale or other requirements with respect to the enforcement of the Lender’s rights hereunder;

 

(iii)     all rights of redemption, appraisement, valuation, stay, extension or moratorium now or hereafter in force under any applicable law in order to prevent or delay the enforcement of this Agreement or the absolute sale of the Collateral or any portion thereof pursuant to the terms of this Agreement, and the Borrower, for itself and all who may claim under it, insofar as it or they may now or hereafter lawfully do so, hereby waives the benefit of such laws; and

 

(iv)     any right the Borrower may have to require the Lender to pursue any other Person for any of the Secured Obligations.

 

(b)     Without limiting the generality of the foregoing, the Borrower hereby waives and releases any and all rights to require the Lender or the other Secured Parties to collect any of the Secured Obligations from any specific item or items of Collateral or from any other party liable as guarantor or in any other manner in respect of any of the Secured Obligations or from any collateral (other than the Collateral) for any of the Secured Obligations.

 

(c)     Any sale of, or the grant of options to purchase (when exercised), or any other realization upon, any Collateral pursuant to the terms of this Agreement shall operate to divest all right, title, interest, claim and demand, either at law or in equity, of the Borrower therein and thereto, and shall be a perpetual bar both at law and in equity against the Borrower and against any and all Persons claiming or attempting to claim the Collateral so sold, optioned or realized upon, or any part thereof, from, through and under the Borrower.

 

 
-19-

 

 

7.6     Discontinuance of Proceedings. In case the Lender shall have instituted any proceeding to enforce any right, power or remedy under this Agreement by foreclosure, sale, entry or otherwise, and such proceeding shall have been discontinued or abandoned for any reason, then, in every such case, the Borrower, the Lender and each holder of any of the Secured Obligations shall be restored to their former positions and rights hereunder with respect to the Collateral, subject to the security interest created under this Agreement, and all rights, remedies and powers of the Lender shall continue as if no such proceeding had been instituted.

 

7.7     Limitation on Duties Regarding Preservation of Collateral. The Lender’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to deal with it in the same manner as the Lender deals with similar property for similar types of accounts. In any event, (i) the Lender shall have no obligation hereunder to take any steps to preserve rights against prior parties to any Collateral and (ii) the Lender, any Secured Party and any of their respective directors, officers, employees or agents shall not be liable for failure to demand, collect or realize upon all or any part of the Collateral or for any delay in doing so or be under any obligation to sell or otherwise dispose of any Collateral upon the request of the Borrower or otherwise.

 

7.8     Application of Proceeds. The Lender shall apply any proceeds from time to time held by it and the net proceeds of any collection, recovery, receipt, appropriation, realization or sale with respect to the Collateral in accordance with the Collateral Agency Agreement. For the avoidance of doubt, it is understood that the Borrower shall remain liable to the extent of any deficiency between the amount of the proceeds of the Collateral and the aggregate amount of the Secured Obligations. If the Borrower is entitled to any portion of the proceeds and if the Lender disposed of the Collateral on credit, the Borrower will only be credited with the payments (a) actually made by the purchaser, (b) received by the Lender, and (c) applied to the indebtedness of such purchaser. If such purchaser fails to pay, the Lender may resell the Collateral and the Borrower shall be credited with the proceeds of the resale. If the Borrower is entitled to any portion of the proceeds and the Lender disposed of the Collateral for non-cash consideration, the Borrower will only be credited with payments received as cash proceeds of non-cash consideration.

 

ARTICLE 8

 

MISCELLANEOUS

 

8.1     Notices. All written communications provided for hereunder shall be sent by first class mail or nationwide overnight delivery service (with charges prepaid) and (i) if to the Lender, addressed to the Lender at the address specified for such communications in the Promissory Notes, or at such other address as the Lender shall have specified to the Company in writing, and (ii) if to the Borrower, addressed to it c/o of the Company at 11475 Great Oaks Way, Suite 150, Alpharetta, Georgia, 30022, Attention: Chief Financial Officer, or at such other address as the Borrower shall have specified to the Lender in writing; provided that any such communication to the Borrower may also, at the option of the Lender, be delivered by any other means either to the Borrower at its address specified above or to any officer of the Borrower.

 

 
-20-

 

 

8.2     Continuing Security Interest. This Agreement shall create a continuing Lien in the Collateral until the release thereof pursuant to Section 8.3.

 

8.3     Release. Upon the indefeasible payment in full in cash of all of the Secured Obligations, the Lender, upon the written request, and at the expense, of the Borrower shall execute and deliver all such documentation necessary to release the Liens created pursuant to this Agreement.

 

8.4     Reinstatement. This Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any amount received by the Lender or any Secured Party hereunder or pursuant hereto is rescinded or must otherwise be restored or returned by the Lender or such Secured Party, as the case may be, upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of the Borrower or upon the appointment of any intervener or conservator of, or trustee or similar official for, the Borrower or any substantial part of the Borrower’s assets, or upon the entry of an order by any court avoiding the payment of such amount, or otherwise, all as though such payments had not been made.

 

8.5     Independent Security. The security provided for in this Agreement shall be in addition to and shall be independent of every other security which the Secured Parties may at any time hold for any of the Secured Obligations hereby secured. The execution of any other agreement or document relating to security interests to secure the Secured Obligations shall not modify or supersede the security interest or any rights or obligations contained in this Agreement and shall not in any way affect, impair or invalidate the effectiveness and validity of this Agreement or any term or condition hereof. The Borrower hereby waives its rights to plead or claim in any court that the execution of any other agreement or document is a cause for extinguishing, invalidating, impairing or modifying the effectiveness and validity of this Agreement or any term or condition contained herein. The Lender shall be at liberty to accept further security from the Borrower or from any third party and/or release such security without notifying the Borrower and without affecting in any way the obligations of the Borrower under this Agreement and the other documents relating hereto.

 

8.6     Amendments. No waiver, amendment, modification or termination of any provision of this Agreement, or consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by the Lender and the Borrower. None of the Collateral shall be released without the prior written consent of the Lender. Any such amendment, waiver or consent shall be effective only in the specific instance and for the specified purpose for which given.

 

8.7     Successors and Assigns. This Agreement shall be binding upon the Borrower and its successors and assigns and shall inure to the benefit of the Lender and the other Secured Parties and their respective successors and assigns and all other Persons who become bound as a debtor to this Agreement. The Borrower may not assign or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the Lender.

 

8.8     Survival. All agreements, statements, representations and warranties made by the Borrower herein or in any certificate or other instrument delivered by the Borrower or on its behalf under this Agreement shall be considered to have been relied upon by the Lender and the Secured Parties and shall survive the execution and delivery of this Agreement and each other document executed in connection herewith until termination thereof or indefeasible payment in full in cash of all of the Secured Obligations regardless of any investigation made by the Lender or the other Secured Parties, or made on their behalf.

 

 
-21-

 

 

8.9     No Waiver; Remedies Cumulative. No failure or delay on the part of the Lender in exercising any right, power or privilege hereunder and no course of dealing between the Borrower and the Lender shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder or thereunder. The rights and remedies herein expressly provided are cumulative and not exclusive of any rights or remedies which the Lender would otherwise have.

 

8.10     Counterparts; Facsimile or Electronic Signatures . This Agreement may be executed in any number of counterparts (or counterpart signature pages), each of which counterparts shall be an original but all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or electronic transmission shall be effective as delivery of a manually executed counterpart of this Agreement.

 

8.11     Headings; Advice of Counsel; Interpretation; Time of the Essence Section and subsection headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect. Each party to this Agreement represents to the other parties to this Agreement that such party has been represented by counsel in connection with this Agreement, that such party has discussed this Agreement with its counsel and that any and all issues with respect to this Agreement have been resolved as set forth herein and therein. No provision of this Agreement shall be construed against or interpreted to the disadvantage of any party hereto by any court or other governmental or judicial authority by reason of such party having or being deemed to have structured, drafted or dictated such provision. Time is of the essence in the performance of this Agreement.

 

8.12     Severability. In case any provision in or obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

8.13     Governing Law; Submission to Jurisdiction and Venue.

 

(a)       Applicable Law . THIS AGREEMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAW OF THE STATE OF DELAWARE (EXCLUDING ANY CONFLICTS OF LAW RULES WHICH WOULD OTHERWISE CAUSE THIS AGREEMENT TO BE CONSTRUED OR ENFORCED IN ACCORDANCE WITH, OR THE RIGHTS OF THE PARTIES TO BE GOVERNED BY, THE LAWS OF ANY OTHER JURISDICTION).

 

 
-22-

 

 

(b)      SUBMISSION TO JURISDICTION. ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT, THE NOTE AGREEMENT, THE NOTES, OR THE OTHER DOCUMENTS ENTERED INTO IN CONNECTION HEREWITH MAY BE BROUGHT IN THE COURTS OF THE STATE OF DELAWARE OR OF THE UNITED STATES FOR THE DISTRICT OF DELAWARE AND, BY EXECUTION AND DELIVERY OF THIS AGREEMENT THE BORROWER HEREBY IRREVOCABLY ACCEPTS, UNCONDITIONALLY, THE JURISDICTION OF THE AFORESAID COURTS WITH RESPECT TO ANY SUCH ACTION OR PROCEEDING. THE BORROWER FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO IT AT ITS ADDRESS PROVIDED PURSUANT TO SECTION 8.1, SUCH SERVICE TO BECOME EFFECTIVE UPON RECEIPT. NOTHING HEREIN SHALL AFFECT THE RIGHT OF LENDER OR ANY SECURED PARTY TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO COMMENCE LEGAL PROCEEDINGS OR OTHERWISE PROCEED AGAINST THE BORROWER IN ANY OTHER JURISDICTION. THE BORROWER HEREBY IRREVOCABLY WAIVES ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE AFORESAID ACTIONS OR PROCEEDINGS ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT BROUGHT IN ANY OF THE AFORESAID COURTS AND HEREBY FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. THE BORROWER AND LENDER WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM OF ANY KIND ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE NOTE AGREEMENT, THE NOTES, ANY OF THE OTHER DOCUMENTS RELATING HERETO, OR THE COLLATERAL .

 

8.14     Indemnities and Expenses. The Borrower hereby agrees to indemnify the Lender, and each other Secured Party, in their capacity as such, the officers, directors, shareholders, controlling persons, employees, agents and servants of the Lender and each other Secured Party, and their respective successors and assigns, officers, directors, employees and agents, and any Person in control of any thereof (each “Indemnified Party” ) from and against any and all claims, damages, losses, liabilities, obligations, penalties, actions, causes of action, judgments, suits, costs, expenses or disbursements (including, without limitation, reasonable attorneys’ and consultants’ fees and expenses) (collectively “Damages” ) of any kind or nature whatsoever which may at any time be imposed on, incurred by or asserted against any Indemnified Party (or which may be claimed against any Indemnified party by any Person) by reason of, or in connection with or in any way relating to or arising out of, this Agreement or any other document relating thereto, any Collateral or any other documents or transactions in connection with or relating thereto, except to the extent determined by a court of competent jurisdiction in a final, non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnified Party. The Borrower further shall, upon demand by any Indemnified Party, pay to such Indemnified Party all costs and expenses incurred by such Indemnified Party in enforcing any rights under this Agreement or any other Documents entered into in connection herewith, including reasonable fees and expenses of counsel. The agreements in this Section 8.14 shall survive the payment or satisfaction in full of the Secured Obligations and the resignation or removal of the Lender or the termination of this Agreement.

 

 
-23-

 

 

8.15     Entire Agreement. This Agreement, together with any other agreement executed in connection herewith, including the other documents relating hereto or referred to herein and therein, is intended by the parties as a final expression of their agreement as to the matters covered hereby and is intended as a complete and exclusive statement of the terms and conditions thereof.

 

8.16     Binding Agreement. When this Agreement is executed and delivered by a Borrower, it shall become a binding agreement by the Borrower in favor of the Lender for the benefit of the Secured Parties.

 

[SIGNATURE PAGE FOLLOWS]

 

 
-24-

 

 

IN WITNESS WHEREOF , the parties hereto have caused this Security Agreement to be duly executed and delivered on the date first above written.

 

 

 

BORROWER:

 

SANUWAVE, INC.

 

 

By:      /s/ Kevin A. Richardson II

Name:     Kevin A. Richardson II
Title: Chairman of the board/CEO

 

 

SANUWAVE SERVICES, LLC

 

 

By:      /s/ Kevin A. Richardson II

Name:     Kevin A. Richardson II
Title: Chairman of the board/CEO

 

 

LEnder:

 

HEALTHTRONICS, INC.

 

By:      /s/ Russell Newman
Name:     Russell Newman
Title: President

 

 

 

 

 

 

 

 

Exhibit 4.2

 

Warrant for the Purchase of 3,310,000

 

Shares of Common Stock

 

Par Value $0.001

 

CLASS K WARRANT AGREEMENT

 

(this “Agreement”)

 

THE HOLDER OF THIS WARRANT, BY ACCEPTANCE HEREOF, BOTH WITH RESPECT TO THE WARRANT AND COMMON STOCK ISSUABLE UPON EXERCISE OF THE WARRANT, AGREES AND ACKNOWLEDGES THAT THE SECURITIES REPRESENTED BY THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND THE LAWS OF ANY APPLICABLE STATE, OR (B) THE SALE OR TRANSFER BEING EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH STATE STATUTES, OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT.

 

This is to certify that, for value received, HealthTronics, Inc. and its successors and assigns (each, a “ Holder ”) is entitled to purchase from SANUWAVE HEALTH, INC. (the “ Company ”), on the terms and conditions hereinafter set forth, all or any part of 3,310,000 shares (which number may be adjusted as provided herein) (“ Warrant Shares ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”), at an initial purchase price of $0.55 per share (which amount may be adjusted as provided herein) (“ Warrant Price ”). Upon exercise of this warrant in whole or in part, a certificate for the Warrant Shares so purchased shall be issued and delivered to the Holder. If, at any time prior to the Expiration Date (as defined below), less than the total warrant is exercised, a new warrant of similar tenor shall be issued for the unexercised portion of the warrant represented by this Agreement.

 

This warrant is granted subject to the following further terms and conditions:

 

1.             (a)     This warrant shall be exercisable, at any time or from time to time after the execution and delivery of this warrant by the Company on the date hereof and shall expire at 5:00 p.m. Eastern Time on the date that is ten (10) years following the date hereof (the “ Expiration Date ”), at the option of the Holder, upon surrender of this warrant to the Company together with a duly completed Exercise Notice, in the form attached hereto, and payment of an amount equal to the Warrant Price multiplied by the number of Warrant Shares for which this warrant is then being exercised, which payment may be satisfied, at the option of the Holder, (i) in cash, (ii) through the exercise of Net Exercise Rights (as defined below), or (iii) through any combination of the foregoing clauses (i) – (ii). “Warrant Shares” as used herein means shares of Common Stock, or any other equity securities into which such Common Stock is converted into or exchanged for in a Company Transaction (as defined below).

 

(b)     Except as provided in the following sentence, any exercise of this warrant hereunder shall be deemed to have been effected immediately prior to the close of business on the day on which this warrant is surrendered to the Company as provided in this warrant. Notwithstanding the foregoing, if an exercise of all or any portion of this warrant is being made in connection with (i) a proposed public offering of any capital stock (or other securities) of the Company, (ii) a proposed Company Transaction, (iii) a proposed issuance or sale of capital stock or any other securities of the Company, or (iv) a proposed transfer of capital stock or other securities of the Company, then, at the election of the Holder, such exercise may be conditioned upon the consummation of such public offering, Company Transaction, or issuance, sale or transfer of capital stock or other securities, in which case (A) such exercise shall be effective concurrently with the consummation of such public offering, Company Transaction, or issuance, sale or transfer of capital stock or other securities, and (B) appropriate modifications will be made to the Exercise Notice to reflect the conditionality specified in this sentence. At the effective time of any exercise of this warrant, the person or entity in whose name or names any certificate for the Warrant Shares shall be issuable upon such exercise as provided in this warrant shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificate.

 

 
 

 

 

(c)     In lieu of exercising the purchase rights represented by this warrant on a cash basis, the Holder may elect to exercise such rights represented by this warrant at any time and from time to time during the term, in whole or in part, on a net-issue basis (the “Net Exercise Right” ) by electing to receive the number of Warrant Shares which are equal in value to the value of this warrant (or any portion thereof to be canceled in connection with such Net Exercise Right) at the time of any such exercise of the Net Exercise Right, by delivery to the principal offices of the Company of this warrant and a completed and duly executed Notice of Exercise appropriately adjusted to indicate that the Holder is exercising the Net Exercise Right.

 

(d)     In the event that the Holder shall elect to exercise the rights represented by this warrant in whole or in part pursuant to the Net Exercise Rights provided in this Section, the Company shall issue to the Holder the number of Warrant Shares determined in accordance with the following formula:

 

X = Y(A-B)

      A

 

where

 

 

X =

the number of Warrant Shares to be issued to the Holder in connection with such Net Exercise Right.

 

 

Y =

the number of Warrant Shares purchasable in respect of which the Net Exercise Right is elected in connection with an exercise of this warrant by the Holder.

 

 

A =

the Fair Market Value of one Warrant Share.

 

 

B =

the Warrant Price in effect as of the date of exercise of the Net Exercise Right (as adjusted pursuant to this warrant).

 

     (e)                     (i)     For purposes of this warrant, the Fair Market Value” of Warrant Shares means on any date specified herein, with respect to Warrant Shares, the amount per share equal to (A) the last sale price of Warrant Shares, regular way, on such date or, if no such sale takes place on such date, the average of the closing bid and asked prices thereof on such date, in each case as officially reported on the principal national securities exchange on which the same are then listed or admitted to trading, (B) if no Warrant Shares are then listed or admitted to trading on any national securities exchange, the last sale price of Warrant Shares, regular way, on such date, or, if no such sale takes place on such date, the average of the reported closing bid and asked prices thereof on such date, as quoted in the Nasdaq Global Market, the Nasdaq Capital Market, the Over-the-Counter Summary or Over-the-Counter Markets, or as published by the National Quotation Bureau, Incorporated or any similar organization, (C) if Fair Market Value is being determined in connection with, or at a time when, a Company Transaction is pending, the fair market value of the Warrant Shares implied by the consideration that will be paid in respect of the class of equity in such Company Transaction that is the same as the Warrant Shares, or (D) if no Warrant Shares are then listed or admitted to trading on any national securities exchange or quoted or published in the over-the-counter market, and no Company Transaction is pending, the Fair Value thereof.

 

 
2

 

 

(ii)     For purposes of this warrant, “Fair Value” of Warrant Shares means on any date specified herein, the fair value thereof (without the application of any discount for a minority interest or lack of liquidity) as of a date which is within 15 days of the date as of which the determination is to be made (A) determined by agreement between the Company and the Holder, or (B) if the Company and the Holder fail to agree, determined jointly by an independent investment banking firm retained by the Company and by an independent investment banking firm retained by the Holder, neither of which firms may be an independent investment banking firm regularly retained by the Company, or (C) if the Company or the Holder shall fail so to retain an independent investment banking firm within ten business days following a written demand by the Holder or the Company to the other party, determined solely by the firm so retained, (D) if the firms so retained by the Company and by the Holder shall be unable to reach a joint determination within 15 business days of the retention of the last firm so retained, determined by another independent investment banking firm which is not a regular investment banking firm of the Company chosen by the first two such firms. The Company shall be responsible for the fees and expenses of all such investment banking firms.

 

(f)     For purposes of this warrant, “Company Transaction” means: (i) a merger or consolidation of the Company with or into any other company, entity or person; (ii) a sale, lease, exchange or other transfer in one transaction or a series of related transactions undertaken with a common purpose of all or a majority of the Company’s then outstanding securities or all or substantially all the Company’s assets; or (iii) a corporate dissolution or liquidation; provided , however , that a Company Transaction shall not include (A) a merger or consolidation of the Company in which the holders of the outstanding voting securities of the Company immediately prior to the merger or consolidation hold at least a majority of the outstanding voting securities of the successor Company immediately after the merger or consolidation, (B) a sale, lease, exchange or other transfer of the Company’s assets to a majority-owned subsidiary of the Company or (C) a transaction undertaken for the principal purpose of reincorporating the Company in a different jurisdiction or creating a holding company, but which in any event does not provide for any distribution of cash or cash equivalents in respect of any security.

 

2.     The Holder acknowledges that (a) this warrant may not be exercised if the issuance of the Warrant Shares upon such exercise would constitute a violation of any applicable federal or state securities laws, or other law or regulation, and (b) the Warrant Shares have not been and will not be registered as of the date of exercise of this warrant under the Securities Act or the securities laws of any state. The Holder acknowledges that this warrant and the Warrant Shares, when and if issued, are and will be “restricted securities” as defined in Rule 144 promulgated under the Securities Act and must be held indefinitely unless subsequently registered under the Securities Act and any other applicable state registration requirements. Except as provided herein, the Company is under no obligation to register the securities under the Securities Act or under applicable state statutes. In the absence of such a registration or an available exemption from registration, sale of the Warrant Shares may be practically impossible. The Holder shall confirm to the Company the representations set forth above in connection with the exercise of all or any portion of this warrant.

 

3.     The number of Warrant Shares purchasable upon the exercise of this warrant and the Warrant Price per share shall be subject to adjustment from time to time as follows:

 

(a)     In the event that the Company should at any time, or from time to time, fix a record date for the effectuation of a split, either forward or reverse, subdivision or combination of the outstanding shares of Common Stock, or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as “ Common Stock Equivalents ”), without payment of any consideration by such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend distribution, split or subdivision if no record date is fixed), the number of Warrant Shares purchasable hereunder shall be appropriately increased or decreased in proportion to such increase or decrease in the aggregate number of shares of Common Stock outstanding and those issuable with respect to such Common Stock Equivalents.

 

 
3

 

 

(b)     Whenever there is an adjustment in the number of Warrant Shares purchasable upon the exercise of this warrant pursuant to the provisions of Section 3(a), the Warrant Price shall be adjusted to an amount proportionate to the adjustment in the number of Warrant Shares.

 

(c)     If at any time, or from time to time, there shall be a recapitalization of the Common Stock (other than a subdivision or combination, or merger or sale of assets transaction provided for elsewhere in this Section 3) provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this warrant the number of shares of Common Stock, Common Stock Equivalents or property of the Company or otherwise, to which the Holder would have been entitled upon such recapitalization assuming this warrant was exercised immediately prior thereto. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 3 with respect to the rights of the Holder of this warrant after the recapitalization to the end that the provisions of this Section 3 (including adjustment of the Warrant Price then in effect and the number of Warrant Shares issuable upon exercise) shall be applicable after that event as nearly equivalent as may be practicable.

 

(d)     If at any time, or from time to time, the Company shall consolidate with or merge into another corporation, or shall sell, lease, or convey to another corporation the assets of the Company as an entity or substantially as an entity (any one or more of such transactions being a “ Corporate Transaction ”), provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this warrant the number of shares of Common Stock, Common Stock Equivalents or property of the Company or otherwise, to which the Holder would have been entitled to receive in such Corporate Transaction assuming this warrant was exercised immediately prior thereto. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 3 with respect to the rights of the Holder of this warrant after the Corporate Transaction to the end that the provisions of this Section 3 (including adjustment of the Warrant Price then in effect and the number of Warrant Shares issuable upon exercise) shall be applicable after that event as nearly equivalent as may be practicable.

 

(e)     Upon each adjustment of the Warrant Price or the number of Warrant Shares issuable upon exercise of this warrant (including pursuant to clause (f) below), the Company at its expense shall promptly compute such adjustment, and furnish the Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request of the Holder at any time, furnish the Holder with a certificate setting forth the Warrant Price and/or the number of Warrant Shares issuable upon exercise of this warrant, as applicable, in each such case upon the date thereof and the series of adjustments leading to such Warrant Price and/or number of Warrant Shares issuable upon exercise of this warrant, as applicable.

 

(f)     Without duplication of the adjustments set forth in Sections 3(a) through 3(e), upon any adjustment of the Company’s Series A warrants (or any warrants issued in replacement or substitution thereof), resulting in (i) a reduction to the exercise price of any Series A warrants, a corresponding reduction, on a dollar-for-dollar basis, will be made to the Warrant Price hereunder, and (ii) an increase in the number of shares issuable upon exercise of the Series A warrants, a corresponding and proportionate increase will be made to the number of Warrant Shares issuable upon exercise of this warrant, provided, that if such increase would result in the Holder having beneficial ownership of 5% or more of the Common Stock (as calculated for purposes of determining compliance with Section 13G or Section 13D under the Securities Exchange Act of 1934, as amended), the Company will first notify the Holder in writing of such proposed adjustment, and such increase will only be effected if the Holder elects in writing for the number of warrants to be so increased, it being understood and agreed that the Holder may, if it so desires, elect for the number of warrants to be increased by a lesser amount than the increase that otherwise would apply as described above.

 

 
4

 

 

4.     The Company covenants and agrees that all Warrant Shares which may be delivered upon the exercise of this warrant will, upon delivery, be free from all taxes, liens, and charges with respect to the purchase thereof; provided, that the Company shall have no obligation with respect to any income tax liability of the Holder.

 

5.     The Company agrees at all times to reserve or hold available a sufficient number of shares of Common Stock or, if applicable, other Warrant Shares, to cover the number of Warrant Shares issuable upon the exercise of this warrant.

 

6.     This warrant shall not entitle the holder hereof to any voting rights or other rights as a shareholder of the Company, or to any other rights whatsoever, except the rights herein expressed, and no dividends shall be payable or accrue in respect of this warrant or the Warrant Shares until or unless, and except to the extent that, this warrant shall be exercised.

 

7.      Compliance with the Securities Act .

 

(a)      Agreement to Comply with the Securities Act; Legend . The Holder, by acceptance of this warrant, agrees to comply in all respects with the provisions of this Section 7 and the restrictive legend requirements set forth on the face of this warrant and further agrees that such Holder shall not offer, sell or otherwise dispose of this warrant or any Warrant Shares to be issued upon exercise hereof except under circumstances that will not result in a violation of the Securities Act. Any certificates evidencing this warrant and all Warrant Shares issued upon exercise of this warrant (unless registered under the Securities Act) shall be stamped or imprinted with a legend in substantially the following form:

 

"THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW."

 

(b)     Representations of the Holder . In connection with the issuance of this warrant, the Holder specifically represents, as of the date hereof, to the Company by acceptance of this warrant as follows:

 

(i)     The Holder is an "accredited investor" as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The Holder is acquiring this warrant and the Warrant Shares to be issued upon exercise hereof for investment for its own account and not with a view towards, or for resale in connection with, the public sale or distribution of this warrant or the Warrant Shares, except pursuant to sales registered or exempted under the Securities Act.

 

 

 
5

 

 

(ii)     The Holder understands and acknowledges that this warrant and the Warrant Shares to be issued upon exercise hereof are "restricted securities" under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that, under such laws and applicable regulations, such securities may be resold without registration under the Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

(iii)     The Holder acknowledges that it can bear the economic and financial risk of its investment for an indefinite period, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the warrant and the Warrant Shares. The Holder has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the warrant and the business, properties, prospects and financial condition of the Company.

 

8.      Representations of the Company . In connection with the issuance of this warrant, the Company specifically represents, as of the date hereof, to the Holder as follows:

 

(a)     All Warrant Shares which may be issued upon the exercise of this warrant have been duly authorized and shall, upon issuance, be validly issued, fully paid and nonassessable; and will be issued in compliance with all applicable federal and state securities laws. The issuance of certificates for Warrant Shares upon exercise of this warrant shall be made without charge to the Holder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise, conversion and related issuance of such shares;  provided , that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Holder.

 

(b)     The Company's summary capitalization table attached hereto is true and complete as of June 15, 2015. Except as set forth on such capitalization table, as of such date, the Company does not have outstanding any capital stock or rights or securities exercisable for or convertible into any capital stock of the Company.

 

(c)     The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties.

 

(d)     All corporate action has been taken on the part of the Company, its officers, directors, and stockholders necessary for the authorization, execution and delivery of this warrant. The Company has taken all corporate action required to make all the obligations of the Company reflected in the provisions of this warrant the valid and enforceable obligations they purport to be, and this warrant constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms. The issuance of this warrant and, upon exercise of this warrant, the Warrant Shares, are not and will not be subject to preemptive rights of any stockholders of the Company. The Company has authorized and reserved for issuance sufficient Warrant Shares to allow for the full exercise of the warrant hereunder.

 

 
6

 

 

(e)     The authorization, execution and delivery of the warrant will not constitute or result in a default or violation of any law or regulation applicable to the Company or any term or provision of the Company’s current Certificate of Incorporation or bylaws, or any material agreement or instrument by which it is bound or to which its properties or assets are subject. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this warrant (including the issuance of Warrant Shares upon the exercise of this warrant).

 

9.     No fractional Warrant Shares shall be issuable upon exercise of this warrant, and the number of Warrant Shares to be issued shall be rounded down to the nearest whole Warrant Share. If a fractional share interest arises upon any exercise or conversion of this warrant, the Company shall eliminate such fractional share interest by paying the Holder an amount in cash computed by multiplying the fractional interest by the Fair Market Value of a full Warrant Share.

 

10.     The Holder may transfer all or part of this w arrant by giving the Company notice of the portion of this w arrant being transferred and setting forth the name , address and taxpayer identification number of the transferee and surrendering this w arrant to the Company for reissuance to the transferee(s) (and Holder, if applicable). The Holder may freely transfer all or part of the Warrant Shares issued upon exercise of this warrant, subject to any applicable restrictions under the Securities Act or the securities laws of any state. The Company may not transfer all or any portion of this Warrant or of the Company’s rights or obligations hereunder.

 

11.      All noti ces a nd o th er communications from the Company to the Holder , or vice ve r sa, shall be deemed delivered and effective when g i ven personally, or three business days after being mailed by first-class regi ste red or ce rtifi ed mail , postage prepaid , or the next business day after being se nt via reputable national overnight delivery se rv ice with s i gnature acknow l edgement of receipt, or the same day if being sent via facsimile with confirmation of delivery, at s uch address or fax number as may have been fu rni s h ed to the Company or the Ho ld er, as the case may be, in writi n g by the Company or such Holder from time to time.

 

All notices to t h e Holder sha ll be addressed as follows :

 

HealthTronics, Inc.

9825 Spectrum Drive, Bldg 3

Austin, TX 78717

Attention: President and General Counsel

Facsimile:

 

with a copy to:

 

Schiff Hardin LLP

233 South Wacker Drive, Suite 6600

Chicago, Illinois 60606

Attention:

Facsimile: 

 

 
7

 

 

A ll n ot i ces to the Company s hall be addressed as fo ll ows:

 

SANUWAVE Health, Inc.

11475 Great Oaks Way, Suite 150

Alpharetta, Georgia

Attention: Chief Financial Officer

Facsimile:

 

with a copy to:

 

Smith, Gambrell & Russell, LLP

Promenade, Suite 310

Atlanta, GA 30309

Attention:

Phone:           

Facsimile:      

 

 

12.     This warrant and any term hereof may be amended by the mutual written agreement of the Company and the Holder, and any right or obligation hereunder may be waived only by an instrument in writing signed by the party against which enforcement of such waiver is sought.

 

13.     In the event of any dispute between the parties concerning the terms and provisions of this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all out-of-pocket costs incurred in such dispute, including reasonable attorneys' fees. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the Holder will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Holder or any other person entitled to the benefit of this warrant requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this warrant.

 

14.     All agreements, representations and warranties contained in this warrant or in any document delivered pursuant hereto shall be for the benefit of the Holder and shall survive the execution and delivery of this warrant and the expiration or other termination of this warrant.

 

15.     This warrant and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts (and facsimile copies of signatures or signatures transmitted via email of a .pdf file shall be deemed original for all purposes), and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.

 

16.     In the event that any provision of this Agreement is found to be invalid or otherwise unenforceable under any applicable law, such invalidity or unenforceability shall not be construed as rendering any other provisions contained herein invalid or unenforceable, and all such other provisions shall be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein.

 

17.     This Agreement shall be governed by and construed in accordance with the internal laws of the State of Nevada, without regard to the principles of conflicts of law thereof.

 

18.     This Agreement shall be binding on and inure to the benefit of the Company and the Holder.

 

 
8

 

 

19.     The Company shall not have any right to redeem all or any portion of the warrant evidenced hereby.

 

*     *     *     *     *

 

 
9

 

 

IN WITNESS WHEREOF, the Company has caused this warrant to be executed by the signature of its duly authorized officer, effective this 15th day of June 2015.

 

 

SANUWAVE HEALTH, INC.

 

By: /s/ Kevin A. Richardson II     

Name: Kevin A. Richardson II

Title: Chairman of the board/CEO

 

The undersigned Holder hereby acknowledges receipt of a copy of the foregoing warrant and acknowledges and agrees to the terms and conditions set forth in the warrant.

 

HEALTHTRONICS, INC.

 

 

By: /s/ Russell Newman                                                         

Name: Russell Newman

Title: President

 

 
10

 

 

Exercise Notice

(to b e signed only upon exercise of w arrant)

 

TO:     SANWUWAVE HEALTH, INC.

 

The Holder of the attached warrant hereby irrevocable elects to exercise the purchase rights represented by the warrant for, and to purchase thereunder, ________________________________ shares of _______ stock of SANUWAVE Health, Inc. and herewith elects to:

 

  □  pay the Exercise Price in cash

 

OR

 

 

pay the Exercise Price by exercise of the Net Exercise Rights in accordance with Section 1 of the warrant

 

OR

 

 

pay the Exercise Price by payment of $_______ in cash and the remainder through the exercise of the Net Exercise Rights in accordance with Section 1 of the warrant

 

Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

 

______________________________________________________________________________

______________________________________________________________________________

______________________________________________________________________________

 

If acquired without registration under the Securities Act of 1933, as amended (“ Securities Act ”), the Holder represents that the Common Stock is being acquired without a view to, or for, resale in connection with any distribution thereof without registration or other compliance under the Securities Act and applicable state statutes, and that the Holder has no direct or indirect participation in any such undertaking or in the underwriting of such an undertaking. The Holder understands that the Common Stock has not been registered, but is being acquired by reason of a specific exemption under the Securities Act as well as under certain state statutes for transactions by an issuer not involving any public offering and that any disposition of the Common Stock may, under certain circumstances, be inconsistent with these exemptions. The Holder acknowledges that the Common Stock must be held and may not be sold, transferred, or otherwise disposed of for value unless subsequently registered under the Securities Act or an exemption from such registration is available. The Company is under no obligation to register the Common Stock under the Securities Act or any state securities law, except as provided in the Agreement for the warrant. The certificates representing the Common Stock will bear a legend restricting transfer, except in compliance with applicable federal and state securities statutes.

 

DATED this ________ day of ________________________________, __________.

 

_______________________________________

Signature

 

11

Exhibit 10.1

 

 

A MENDMENT TO PROMISSORY NOTES

 

This AMENDMENT TO PROMISSORY NOTES (the “ Amendment ”) is entered into as of June 15, 2015 by and between SANUWAVE, INC ., a Delaware corporation (the “ Borrower ”), SANUWAVE HEALTH , INC ., a Nevada corporation (the “ Parent ”), and HEALTHTRONICS, INC. , a Georgia corporation (“ Healthtronics ”).

 

W I T N E S S E T H :

 

WHEREAS, the Borrower and Healthtronics entered into that certain Promissory Note due August 1, 2015 dated August 1, 2005 in the original principal amount of $2,000,000 and that certain Promissory Note due August 1, 2015 dated August 1, 2005 in the original principal amount of $2,000,000 (as may have been amended from time to time, collectively, the “ Promissory Notes ”), pursuant to which Healthtronics extended loans to the Borrower, and the Borrower and Healthtronics desire to amend the Promissory Notes (capitalized terms, as used herein, shall have the meaning set forth in the Promissory Notes, unless the context otherwise requires);

 

WHEREAS , the aggregate outstanding principal amount under the Promissory Notes as of the date hereof is $5,372,743; and

 

WHEREAS, the Borrower has requested that Healthtronics amend certain provisions of the Promissory Notes and Healthtronics has agreed to the amendments set forth in this Amendment, all on the terms and subject to the conditions set forth herein.

 

For the purpose of conforming the same to the intention of the parties and for other value received, it is hereby agreed that each of the Promissory Notes shall be amended and modified in the following particulars:

 

Section 1. Amendments to the Promissory Note s. Effective upon satisfaction of the conditions set forth in Section 3 hereof, each Promissory Note is hereby amended as follows:

 

A.     The definition of Stated Maturity Date of “August 1, 2015” in the first paragraph of the Promissory Notes shall be deleted and replaced with “January 31, 2017.”

 

B.      Section 2 .1 shall be deleted in its entirety and the following substituted in lieu thereof:

 

2.1       Interest . This Note shall accrue daily interest from the date hereof on the outstanding Principal Amount of this Note at six percent (6%) per annum (the “ Interest Rate ”), provided, for the period commencing August 1, 2015 through the date this Note is paid in full, the Interest Rate shall be eight percent (8%) per annum, provided, further that, during any period when an Event of Default shall be in existence, the then applicable Interest Rate shall increase by two percent (2%) per annum. Such interest shall be paid to Healthtronics quarterly in arrears on each March 31, June 30, September 30 and December 31 of each calendar year and on the Stated Maturity Date and any other date upon which any Principal Amount hereunder is paid, or if any such day is not a business day, on the next succeeding business day (each an “ Interest Payment Date ”).

 

 
1

 

 

C.      Section 2 . 2 shall be deleted in its entirety and the following substituted in lieu thereof:

 

2.2     [Intentionally Omitted].

 

D.      Section 3.1 shall be deleted in its entirety and the following substituted in lieu thereof:

 

3.1      Payments .

 

(a)      Mandatory Payment on the Stated Maturity Date . The outstanding Principal Amount of this Note together with all accrued and unpaid interest thereon and all other amounts due to Healthtronics under this Note will be payable on the Stated Maturity Date in cash.

 

(b)      Mandatory Prepayments . The Borrower shall make a mandatory prepayment of the Principal Amount of this Note in (i) an amount equal to twenty percent (20%) of the proceeds received by the Borrower, the Borrower’s parent company, SANUWAVE Health, Inc., a Nevada corporation (the “ Parent ”), or any subsidiary of the Borrower or the Parent pursuant to (a) the issuance or sale by the Borrower, the Parent or any of their subsidiaries of any equity securities or any securities exercisable for or convertible into or exchangeable for any equity securities, or receipt by the Borrower, the Parent or any of their subsidiaries of capital contributions in cash or (b) the licensing by Borrower of any of Borrower’s products or patents or other intellectual property rights, and (ii) without limiting the restrictions contained in Section 7.12, an amount equal to one hundred percent (100%) of the proceeds received by the Parent, the Borrower or any subsidiary of the Parent or the Borrower from (a) borrowings through secured or unsecured debt (other than debt expressly permitted by Section 7.12(iii)), (b) a sale of all or a material portion of the assets of the Parent, the Borrower or any of their respective subsidiaries and (c) any sale of assets (including any patents or other intellectual property rights) of the Parent, the Borrower or any of their respective subsidiaries (other than sales of inventory in the ordinary course of business) for which the proceeds from such sales exceed $20,000 individually or $50,000 in the aggregate. Such mandatory prepayments shall be made within one (1) business day after the receipt of such proceeds.

 

E.      Section 4 .1 shall be deleted in its entirety and the following substituted in lieu thereof:

 

4.1      Change of Control of the Borrower . If a Change of Control shall occur, the Borrower shall pay the entire outstanding Principal Amount together with all accrued and unpaid interest thereon and all other amounts due to Healthtronics under this Note on the date of such Change of Control.

 

F.      Section 4 . 2 shall be deleted in its entirety and the following substituted in lieu thereof:

 

 
2

 

 

4.2     [Intentionally Omitted].

 

G.      Section 4 . 3 shall be deleted in its entirety and the following substituted in lieu thereof:

 

4.3      Definitions .

 

“Change of Control” means (i) the merger, consolidation or other combination of the Parent with any person in which the stockholders of the Parent immediately prior to such transaction in the aggregate cease to own and control more than 50% of the voting securities of the person surviving or resulting from such transaction (or the ultimate parent thereof), (ii) if any person (as such term is used in section 13(d) and section 14(d)(2) of the Exchange Act as in effect on June 15, 2015) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act) become the “beneficial owners” (as such term is used in Rule 13d-3 under the Exchange Act as in effect on June 15, 2015), directly or indirectly, of more than 50% of the total voting power of all classes then outstanding of the Parent’s voting stock, (iii) the Parent ceases to directly own and control 100% of the issued and outstanding equity interests of the Borrower, (iv) the sale, conveyance or other transfer of all or substantially all of the assets of the Borrower or the Parent or (v) the Borrower fails to own and control 100% of the issued and outstanding equity interests in each of its subsidiaries.

 

H.      Article V shall be deleted in its entirety and the following substituted in lieu thereof:

 

ARTICLE V

[INTENTIONALLY OMITTED]

 

I.      Article VI shall be deleted in its entirety and the following substituted in lieu thereof:

 

ARTCLE VI

EVENTS OF DEFAULT

 

6.1      Events of Default; Remedies . If any of the following events shall occur and be continuing for any reason whatsoever (and whether such occurrence shall be voluntary or involuntary or come about or be effected by operation of law or otherwise) (each such event herein termed an “ Event of Default ”):

 

6.1.1     the Borrower shall fail to make any payment of (i) Principal Amount of this Note when due, whether at maturity by acceleration or otherwise or (ii) any interest on this Note or other amount payable by the Borrower under this Note;

 

6.1.2     (i) the Borrower defaults in the performance of or compliance with any term contained in Sections 7.11, 7.12 or 7.15 or in the Security Agreement or (ii) the Parent defaults in the performance of or compliance with any term contained in Sections 7.11 or 7.12;

 

 
3

 

 

6.1.3     the Parent, the Borrower or any subsidiary defaults in the performance of or compliance with any term contained in this Note or any other agreement, document or instrument executed and delivered pursuant hereto and such default continues for 15 days after the earlier of (i) the Parent, the Borrower or a subsidiary becoming aware of such default or (ii) receipt by the Parent, the Borrower or any subsidiary of notice of such default from Healthtronics;

 

6.1.4     there occurs an Event of Default (under and as defined in any other evidence of indebtedness of the Parent, the Borrower or any subsidiary owing to Healthtronics);

 

6.1.5     the Parent, the Borrower or any subsidiary shall:

 

(a)     commence a voluntary case under Title 11 of the United States Code as from time to time in effect, or authorize, by appropriate proceedings of its board of managers or other governing body, the commencement of such a voluntary case;

 

(b)     have filed against it a petition under said Title 11 which shall not have been dismissed within 30 days after the date on which said petition is filed, or file an answer or other pleading within said 30-day period admitting or failing to deny the material allegations of such a petition, or seeking, consenting to or acquiescing in the relief therein provided, or fail to controvert timely the material allegations of any such petition;

 

(c)     have entered against it an order for relief in any involuntary case commenced under said Title 11;

 

(d)     seek relief as a debtor under any applicable law, other than said Title 11, of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or alteration of the rights of creditors, or consent to or acquiesce in such relief;

 

(e)     have entered against it any order by a court of competent jurisdiction (i) finding it to be bankrupt or insolvent, (ii) ordering or approving its liquidation, reorganization or any modification or alteration of the rights of its creditors or (iii) assuming custody of, or appointing a receiver or other custodian for, all or a substantial part of its property; or

 

(f)     make an assignment for the benefit of, or enter into a composition with, its creditors or appoint or consent to the appointment of a receiver or other custodian for all or a substantial part of its property;

 

6.1.6     any representation or warranty made in writing by or on behalf of the Parent, the Borrower or any subsidiary or any officer of the Parent, the Borrower or any subsidiary in this Note, the Security Agreement or any other document or writing furnished in connection with the transactions contemplated hereby or thereby proves to have been false or incorrect in any material respect on the date as of which made;

 

 
4

 

 

6.17     the Security Agreement shall cease to be in full force and effect or the Borrower shall contest or deny the validity or enforceability of, or deny that it has any liability or obligations under, the Security Agreement, or Healthtronics does not have or ceases to have a valid first priority perfected security interest in all of the collateral referred to in the Security Agreement; or

 

6.1.8     the Parent shall have any direct subsidiary (other than Borrower), own or acquire any assets (other than the equity interests of the Borrower) or engage in any operations or business (other than activities incidental to being a holding company).

 

6.2      Remedies on Default .

 

6.2.1      Acceleration .

 

(a)     If an Event of Default with respect to the Borrower described in Section 6.1.5 has occurred this Note shall automatically become immediately due and payable.

 

(b)     If any other Event of Default has occurred and is continuing, Healthtronics may, at any time at its option, by notice to the Borrower, declare this Note to be immediately due and payable.

 

Upon this Note becoming due and payable under this Section 6.2.1, whether automatically or by declaration, this Note will forthwith mature and the entire unpaid Principal Amount of this Note, plus  all accrued and unpaid interest and all other amounts due and payable by the Borrower hereunder, shall all be immediately due and payable, in each and every case without presentment, demand, protest or further notice, all of which are hereby waived and Healthtronics, may proceed to enforce payment of such amount or part thereof in such manner as it may elect and Healthtronics may proceed to protect and enforce its rights by suit in equity, action at law and/or other appropriate proceeding either for specific performance of any covenant, provision or condition contained in this Note or the Security Agreement, or in aid of the exercise of any power granted in this Note or the Security Agreement

 

6.3      Annulment of Defaults . An Event of Default shall not be deemed to be in existence for any purpose of this Note if Healthtronics shall have waived such event in writing or stated in writing that the same has been cured to its reasonable satisfaction. No waiver or statement of satisfactory cure pursuant to this Section 6.3 shall extend to or affect any subsequent or other Event of Default not specifically identified in such waiver or statement of satisfactory cure or impair any of the rights of Healthtronics upon the occurrence thereof.

 

 
5

 

 

6.4      Waivers . The Parent and the Borrower each hereby waives to the extent not prohibited by provisions of applicable law which cannot be waived (a) all presentments, demands for performance and notices of nonperformance (except to the extent specifically required by the provisions hereof), (b) any requirement of diligence or promptness on the part of Healthtronics in the enforcement of its rights under the provisions of this Note or the Security Agreement, (c) any and all notices of every kind and description which may be required to be given by any legal requirement, and (d) any defense of any kind (other than payment) which it may now or hereafter have with respect to its obligations and liability under this Note and the Security Agreement

 

6.5      Course of Dealing . No course of dealing between the Parent, the Borrower or any subsidiary on the one hand, and Healthtronics on the other hand, shall operate as a waiver of the parties’ rights under this Note. No delay or omission in exercising any right under this Note shall operate as a waiver of such right or any other right. A waiver on any one occasion shall not be construed as a waiver of or bar to any right or remedy on any other occasion. No waiver or statement of satisfactory cure or consent shall be binding upon Healthtronics unless it is in writing and signed by Healthtronics as may be required by the provisions of this Note.

 

J.      Section 7.2 shall be amended by deleting the reference to “telecopied” contained therein and inserting “facsimile” in lieu thereof.

 

K.      Section 7.2.1 and 7.2.2 shall be deleted in their entirety and the following substituted in lieu thereof:

 

7.2.1     If to Healthtronics, to:

 

HealthTronics, Inc.

9825 Spectrum Drive, Bldg 3

Austin, TX 78717

Attention: President and General Counsel

Facsimile:

 

with a copy (which shall not constitute notice) to:

 

Schiff Hardin LLP

233 South Wacker Drive, Suite 6600

Chicago, Illinois 60606

Attention:

 

Phone:

Facsimile:

 

 
6

 

 

7.2.2     If to the Borrower, to:

 

SANUWAVE, Inc.

11475 Great Oaks Way, Suite 150

Alpharetta, GA 30022

Attention: Chief Financial Officer

Facsimile:

 

with a copy (which shall not constitute notice) to:

 

Smith, Gambrell & Russell, LLP

Promenade, Suite 310

Atlanta, GA 30309

Attention:

Phone:      

Facsimile:      

Email:       

 

 

L.      Section 7.3 shall be deleted in its entirety and the following substituted in lieu thereof:

 

7.3      Expenses . The Borrower agrees to pay or reimburse Healthtronics on demand for and save Healthtronics harmless against any and all losses, liabilities, costs and expenses, including attorneys’ fees and expenses, incurred by Healthtronics in connection with this Note and the Security Agreement and the enforcement or preservation of any of the rights and remedies of Healthtronics under this Note and the Security Agreement including, without limitation, the costs of collection of this Note.

 

M.      Section 7.9 shall be deleted in its entirety and the following substituted in lieu thereof:

 

7.9       Assignment . The Borrower may not assign its rights or obligations under this Note. The Holder may not assign all or any of its rights or obligations under this Note without the prior written consent of the Borrower;  provided however , that no such consent of the Borrower shall be required with respect to any such assignment by the Holder (a) to any affiliate of the Holder, or to a purchaser of all or substantially all of the assets of the Holder or its subsidiaries, or (b) if any Event of Default has occurred that has not been cured by the Borrower or waived by the Holder.

 

N.      Section 7.10 shall be deleted in its entirety and the following substituted in lieu thereof:

 

7.10       Further Assurances . Each of the Parent and the Borrower agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be necessary or desirable in order to implement the transactions contemplated by this Note as requested by Healthtronics.

 

 
7

 

 

 

O.

The following provision is included as Section 7.11 :

 

7.11       Board Observation Rights .

 

 

7 .11.1

For so long as any amounts remain outstanding hereunder, Healthtronics shall have the right to appoint one representative to exercise the rights as conferred pursuant to this Section 7.11 (such representative being referred to as the “ Observation Party ”) and shall notify the Borrower of the identity of such person.

 

 

7.11.2

The Borrower shall notify the Observation Party of the date and time for each general or special meeting of the board of directors, board of managers or similar governing body (or any committee thereof) of the Borrower and of the Parent or of the adoption of any resolutions by any such body or committee by written consent (describing in reasonable detail the nature and substance of such action) at the time notice is provided to the directors or managers of the Borrower or the Parent, as applicable, and concurrently deliver to the Observation Party any materials delivered to directors or managers of the Borrower or the Parent, as applicable, including a draft of any resolutions proposed to be adopted by written consent.

 

 

7.11.3

The Observation Party shall be entitled to, or to select one representative to, attend and participate (but not vote) in all meetings of the board of directors, board of managers or other governing body (including any committee thereof) of the Borrower and of the Parent, including telephonic meetings. The Observation Party (or its representative) shall be entitled to receive all written materials and other information at the same time and in the same manner as given to the participants in such meetings. The Borrower or the Parent shall reimburse Healthtronics for all reasonable and documented out-of-pocket costs and expenses incurred by the Observation Party in connection with traveling to and from and attending such meetings.

 

 

P.

The following provision is included as Section 7.12 :

 

 

7.12

Restrictions on Material Transactions . Without the prior written consent of Healthtronics, neither the Parent, the Borrower nor any of their subsidiaries shall (i) merge into or consolidate with any other entity; make any substantial change in the nature of their business as conducted as of June 15, 2015; (ii) acquire all or substantially all of the assets of any other entity; sell, lease, transfer or otherwise dispose of all or a substantial or material portion of such person’s assets except in the ordinary course of its business (other than the licensing of Borrower’s products or patents or other intellectual property rights); (iii) create, incur, assume or permit to exist any indebtedness or liabilities resulting from borrowings, loans or advances, whether secured or unsecured, matured or unmatured, liquidated or unliquidated, joint or several other than unsecured indebtedness or liabilities of the Borrower resulting from borrowings in an aggregate outstanding amount not to exceed $200,000; or (iv) (a) make any dividend or distribution to any holders of its equity securities, or any securities exercisable for or convertible into or exchangeable for any equity security (other than dividends from subsidiaries of the Borrower to the Borrower), (b) purchase or redeem any of its equity securities, (c) pay any management fees or similar fees to any of its equity holders or any affiliate thereof, or (d) set aside funds for any of the foregoing.

 

 
8

 

 

 

Q.

The following provision is included as Section 7.13 :

 

 

7.13

Security Agreement . The indebtedness evidenced by this Note and the obligations created hereby are secured by, among other things, the grant of a security interest in favor of Healthtronics in, or the conveyance to Healthtronics of title to, all assets of the Borrower and each of its domestic subsidiaries now owned or hereafter acquired, as further described in that certain Security Agreement executed and delivered by the Borrower and each of its domestic subsidiaries to Healthtronics on June 15 2015 (the “ Security Agreement ”).

 

 

R.

The following provision is included as Section 7.14 :

 

 

7.14

Confession of Judgment . The Borrower hereby authorizes and empowers any attorney of any court of record to appear for the Borrower and to confess judgment as often as necessary against the Borrower in favor of Healthtronics, as of any term or time, for the above sums plus interest due, together with costs and other expenses of legal proceedings and reasonable attorneys’ fees, with release of all errors and waive all rights of appeal If a copy of this Note verified by an affidavit shall have been filed in the proceeding, it will not be necessary to file the original as a warrant of attorney. The Borrower waives the right to any stay of execution and the benefit of all exemption laws now or hereafter in effect. No single exercise of the foregoing warrant in power to confess judgment will be deemed to exhaust the power, whether or not any such exercise shall be held by any court to be invalid, voidable or void; but the power will continue undiminished and may be exercised from time to time as Healthtronics may elect until the Principal Amount and all other amounts payable under this Note are paid in full. The Borrower hereby waives and releases any and all claims or causes of action, which the Borrower might have against any attorney acting under the terms of authority which the Borrower has granted herein arising out of or connected with the confession of judgment hereunder.

 

 

S.

The following provision is included as Section 7.1 5 :

 

 

7.15

Notices of Event of Default . Immediately, and in any event within one (1) business day, after obtaining knowledge of the occurrence of any Event of Default or event which, with notice or passage of time or both, would constitute an Event of Default, the Borrower shall give written notice thereof to Healthtronics and specify the nature and period of existence thereof and what action the Borrower proposes to take with respect thereto.

 

 
9

 

 

 

T.

The following provision is included as Section 7.1 6 :

 

 

7.16

Replacement of Note . On the date hereof, Borrower will execute and deliver a replacement Note evidencing the terms of this Note (as amended by that certain Amendment To Promissory Notes dated as of June 15, 2015 between the Borrower and Healthtronics); and upon any future request of Healthtronics, the Borrower agrees to execute and deliver a replacement Note evidencing the terms of this Note (as amended by that certain Amendment To Promissory Notes dated as of June 15, 2015 between the Borrower and Healthtronics) upon delivery of the original Note (or, to the extent the original Note has been lost or mutilated, a lost note affidavit from Healthtronics).

 

Section 2.     Representations and Warranties . Each of the Parent and the Borrower, jointly and severally, represents and warrants to Healthtronics that (a) the execution and delivery of this Amendment has been duly authorized by all requisite corporate action on behalf of the Parent and the Borrower, this Amendment has been duly executed and delivered by an authorized officer of the Parent and the Borrower, and each of the Parent and the Borrower has obtained all authorizations, consents, and approvals necessary for the execution, delivery and performance of this Amendment and such authorizations, consents and approvals are in full force and effect, (b) this Amendment and each Promissory Note (as amended by this Amendment) constitutes the legal, valid and binding obligation of each of the Parent and the Borrower enforceable against the Parent and the Borrower in accordance with its terms, (c) neither the execution nor delivery of this Amendment or the Security Agreement nor fulfillment of nor compliance with the terms and provisions of the Promissory Notes, this Amendment or the Security Agreement will conflict with, or result in a breach of the terms, conditions or provisions of, or constitute a default under, or result in any violation of, or result in the creation of any lien (other than liens created pursuant to the Security Agreement) upon any of the properties or assets of the Parent, the Borrower or any of its subsidiaries pursuant to, the charter, limited liability company operating agreement, partnership agreement, by-laws, limited liability company operating agreement or partnership agreement of the Parent, the Borrower or any of its subsidiaries, any award of any arbitrator or any agreement (including any agreement with stockholders, members or partners), instrument, order, judgment, decree, statute, law, rule or regulation to which the parent, the Borrower or any of its subsidiaries is subject, (d) before and after giving effect to this Amendment, no Event of Default has occurred and is continuing under either Promissory Note, (e) Healthtronics has a valid, perfected, first-priority lien upon and security interest in all assets of the Borrower and each of its domestic subsidiaries whether now owned or hereafter acquired, and (f) immediately before and after giving effect to this Amendment, (i) the sum of the debts and liabilities of the Borrower (including, without limitation, contingent liabilities of the Borrower) is not greater than all of the assets of the Borrower at a fair valuation, (ii) the present fair salable value of the assets of the Borrower is not less than the amount that will be required to pay the probable liability of the Borrower on its debts as they become absolute and matured, and (iii) the Borrower is not otherwise insolvent as defined in, or otherwise in a condition which could in any circumstances then or subsequently render any transfer, conveyance, obligation or act then made, incurred or performed by it avoidable or fraudulent pursuant to, any law, rule or regulation that may be applicable to the Borrower pertaining to bankruptcy, insolvency or creditors’ rights, fraudulent conveyance or fraudulent transfers or preferences.

 

 
10

 

 

Section 3.     Conditions to Effectiveness . The amendments to the Promissory Notes set forth in Section 1 hereof shall become effective as of the date (the “ Effective Date” ) when each of the following conditions has been satisfied:

 

(a)          The representations and warranties of the Parent, the Borrower and each of its subsidiaries set forth in the Promissory Notes, this Amendment, the Security Agreement and in all agreements, documents and instruments executed and delivered pursuant to the Promissory Notes or this Amendment shall be true and correct in all material respects when made and as of the date of this Amendment.

 

(b)            After giving effect to the terms of this Amendment, there shall be no Event of Default or event which, with notice or passage of time or both, would constitute an Event of Default under the Promissory Notes.

 

(c)           On or before the date hereof, the Borrower and each of its domestic subsidiaries shall execute and deliver the Security Agreement which shall be in form and substance satisfactory to Healthtronics and Healthtronics shall have a valid, perfected, first-priority lien upon and security interest in all assets of the Borrower and each of its domestic subsidiaries.

 

(d)           On or before the date hereof, the Borrower and each of its domestic subsidiaries shall execute and deliver deposit account control agreements in form and substance satisfactory to Healthtronics and each executed by the applicable depository bank.

 

(e)           On or before the date hereof, the Borrower and each of its domestic subsidiaries shall execute and deliver intellectual property security agreements in form and substance satisfactory to Healthtronics.

 

(f)           On or before the date hereof, the Parent shall execute and deliver the Class K Warrant Agreement to Healthtronics evidencing fully vested warrants for the purchase of the number of shares of common stock of the Parent as more fully set forth in such Class K Warrant Agreement.

 

(g)           The Borrower shall have paid the fees and expenses of Schiff Hardin LLP, special counsel to Healthtronics, in connection with this Amendment, the Security Agreement, the Class K Warrant Agreement and the Promissory Notes which shall not exceed $15,000.

 

Section 4.     Reference to and Effect on Promissory Notes .

 

A.     From and after the date hereof, the Promissory Notes shall be deemed to mean the Promissory Notes, as amended hereby.

 

B.     This Amendment represents a modification only and is not, and should not be construed as, a novation of the Promissory Notes. Nothing contained in this Amendment shall be construed to narrow the scope of the security interest of Healthtronics in any of the Collateral (as defined in the Security Agreement) or the perfection or priority thereof or to impair or otherwise limit any of the rights, powers, privileges or remedies of Healthtronics under the Promissory Notes or the Security Agreement.

 

 
11

 

 

C.     The Parent and the Borrower each acknowledges and agrees that the agreement of Healthtronics to amend the terms of the Promissory Notes pursuant to and as reflected in this Amendment does not and shall not create (nor shall the Parent or the Borrower rely upon the existence of or claim or assert that there exists) any obligation of Healthtronics to consider or agree to any further amendments and, in the event that Healthtronics subsequently agrees to consider any further amendment, neither the existence of this Amendment, nor any other conduct of Healthtronics, shall be of any force or effect on consideration or decision with respect to any such requested amendment, and Healthtronics shall have no obligation whatsoever to consider or agree to amend the Promissory Notes or forbear or waive any other default or Event of Default.

 

Section 5.     Release . Each of the Parent and the Borrower, for itself and on behalf of its heirs, legal representatives, affiliates, successors and assigns, hereby: (a) expressly waives, releases and relinquishes any and all defenses, affirmative defenses, setoffs, claims, counterclaims and causes of action of any kind or nature whatsoever which the Borrower has asserted, or might assert, against Healthtronics or any of its affiliates or any shareholders, members, partners, employees, directors, officers, representatives or agents of Healthtronics or any of its affiliates (collectively, the “ Released Parties ”) with respect to the Promissory Notes or the indebtedness evidenced thereby, or with respect to any other documents or instruments now or heretofore evidencing, securing or in any way relating to the Promissory Notes or the indebtedness evidenced thereby, including without limitation the Purchase Agreement, or with respect to any other matter, cause or thing relating in any way to the Promissory Notes or the Purchase Agreement; (b) expressly remises, releases, acquits, satisfies and forever discharges each Released Party from any and all manner of debts, accountings, bonds, warranties, representatives, covenants, promises, contracts, controversies, agreements, liabilities, obligations, expenses, damages, judgments, executions, actions, claims, demands and causes of action of any nature whatsoever, whether at law or in equity, either now accrued or hereafter maturing, which the Borrower now has or hereafter can, shall or may have by reason of any matter, cause or thing, from the beginning of the world to and including the date hereof relating in any way to the Promissory Notes, including specifically, but without limitation, matters arising out of or relating to: (i) the Promissory Notes or the indebtedness evidenced thereby, including but not limited to, the administration thereof; (ii) the exercise or attempted exercise by any Released Party of any of its rights and remedies against the Borrower or the assets thereof on account of any Event of Default or otherwise; (iii) any other agreement or transaction between the Borrower and any Released Party relating in any way to the Promissory Notes and (iv) any Event of Default; and (c) expressly covenants and agrees never to institute or cause to be instituted or continue prosecution of any suit or other form of action or proceeding of any kind or nature whatsoever against any Released Party by reason of or in connection with any of the foregoing matters, claims or causes of action.

 

Section 6.     Acknowledgement of Indebtedness . As of June 15, 2015, the Borrower acknowledges and agrees that the Borrower is indebted to Healthtronics under the Promissory Notes in the aggregate principal amount of $5,372,743 plus accrued and unpaid interest since March 31, 2015. The Borrower acknowledges and agrees that it owes the amounts referred to above without defense, right of offset, set off, or counterclaims.

 

 
12

 

 

Section 7.       Joinder by the Parent. The Parent hereby joins each Promissory Note and agrees to comply with the provisions thereof as if the Parent were an original signatory thereto.

 

Section 8.      Miscellaneous .

 

(a)     This Amendment may be executed in two or more counterparts, each of which, when fully executed, shall be deemed an original; and all of said counterparts taken together shall be deemed to constitute one and the same Amendment. Delivery of an executed counterpart of a signature page to this Amendment by facsimile or electronic transmission shall be effective as delivery of a manually executed counterpart of this Amendment.

 

(b) THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS.

 

 

[Signatures on Next Page]

 

 
13

 

   

IN WITNESS WHEREOF , the parties hereto have executed this Amendment as of June 15, 2015.

 

 

Borrower :

 

SANUWAVE, INC.

 

By: /s/ Kevin A. Richardson II

Name: Kevin A. Richardson II

Title: Chairman of the board/CEO

 

 

Parent :

 

SANUWAVE HEALTH, INC.

 

By: /s/ Kevin A. Richardson II

Name: Kevin A. Richardson II

Title: Chairman of the board/CEO

 

 

Healthtronics :

 

HEALTHTRONICS, INC.

 

By: /s/ Russell Newman           

Name: Russell Newman

Title: President

 

 

 

14

Exhibit 99.1

 

 

 

 

FOR IMMEDIATE RELEASE

 

 

SANUWAVE announces strengthening of balance sheet with AMENDMENT AND EXTENSION OF PROMISSORY NOTES

 

ALPHARETTA, GA, June 18 , 201 5 – SANUWAVE Health, Inc. (OTC QB : SNWV) today announced it has entered into an amendment to certain provisions of the two promissory notes dated August 1, 2005 between the Company and HealthTronics, Inc. with an aggregate outstanding principal balance of $5,372,743.

 

The amendment provides for the extension of the due date of the promissory notes to January 31, 2017. I n connection with the amendment, the Company entered into a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. In addition, the Company, in connection with the amendment, issued to HealthTronics, Inc. an aggregate total of 3,310,000 Class K warrants to purchase shares of common stock at an exercise price of $0.55 per share, subject to anti-dilution protection. The warrants vested upon issuance and expire after ten years.

 

"We are pleased that we were able to successfully extend the terms of our promissory notes with HealthTronics, from whom we acquired SANUWAVE’s extensive patent and technology platform in 2005. As a result, we now have a much stronger balance sheet and the financial flexibility to pursue a number of our strategic initiatives and growth strategies slated for 2015 and beyond," commented Kevin A. Richardson II, SANUWAVE’s Chairman of the board of directors.

 

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE ® , is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron ® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron ® and orthoPACE ® devices in Europe, Asia and Asia/Pacific . In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

 

 
 

 

 

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

 

For additional information about the Company, visit www.sanuwave.com .

 

Contact:

 

Todd Markey

IR Partners

818-280-6800

markey@irpartnersinc.com  

 

Daniel Conway

DC Consulting, LLC
407-792-3333

investorinfo@dcconsultingllc.com

 

SANUWAVE Health, Inc.

Kevin Richardson

Chairman of the Board

617-778-9223

Barry Jenkins

Chief Financial Officer and COO

678-578-0103

investorrelations@sanuwave.com